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                          ABSTRACT  
 
PROBIOTIC METABOLISM OF HUMAN MILK OLIGOSACCHARIDES (HMOs) 
AND PREBIOTICS 
 
Taksawan Thongaram 
Department of Food Science and Human Nutrition 
University of Illinois at Urbana-Champaign, 2014 
Michael J. Miller, Adviser 
 
Human milk contains a high concentration of complex oligosaccharides (HMOs) that 
are believed to confer physiological benefits to infants such as immunomodulation and 
prevention of pathogen attachment. In addition, it has been postulated that HMOs serve as 
prebiotics by promoting the growth of bifidobacteria in the infant gastrointestinal tract (GIT). 
In this study, the first aim was to investigate the probiotic metabolism of HMOs and HMO 
precursors. Growth parameters were determined by inoculating glucose-grown cultures into 
basal deMan Rogosa Sharpe (MRS) (no added glucose) with 1% carbohydrate (+0.5 g/l L-
cysteine for bifidobacteria) and measuring growth over 48 h.  Cultures were grown in 
microtiter plates, which were incubated under 90% N2, 5% CO2 and 5% H2 at 37
o
C.  Results 
indicated that: (1) N-acetyl-D-glucosamine (GlcNAc) was widely used by the lactobacilli, but 
B. breve ATCC15700 was the only bifidobacteria strain that could utilize this carbohydrate, 
(2) none of the bifidobacteria and very few lactobacilli could utilize either free L-fucose (L. 
rhamnosus GG and L. rhamnosus DR20) or sialic acid (L. plantarum LP‐66), (3)  none of the 
lactobacilli could ferment the HMOs: 3’-Sialyllactose (3’-SL), 6’-Sialyllactose (6’-SL), 2’-
Fucosyllactose (2’-FL) and 3’- Fucosyllactose (3’-FL), yet four lactobacilli demonstrated 
moderate growth with LNnT, (4) amongst the bifidobacteria strains, only B. infantis ATCC 
15697 and B. infantis M-63 were able to ferment 3'-SL, 6’-SL, 2’-FL and 3’-FL, (5) when B. 
infantis M‐63 was grown with 3’-SL, no sialic acid accumulated in the growth media, but 
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when it was grown with 2’-FL, the 44% of the L‐fucose liberated from 2’-FL remained in the 
media and (6) B. infantis, B. breve, L. acidophilus, L. plantarum and L. reuteri were able to 
ferment Lacto-N-neotetraose (LNnT), which was confirmed by High Performance Liquid 
Chromatography (HPLC) analysis.  Thus, there are differences in utilization profiles of milk 
oligosaccharides among lactobacilli and bifidobacteria strains, information that may aid in 
the development of future synbiotic formulations. 
The second aim was to investigate the consumption of LNnT by selected lactobacilli 
and bifidobacteria. We found that LNnT was a growth factor for B. infantis, B. breve, L. 
acidophilus, L. plantarum and L. reuteri.  In this study, HPLC and Thin Layer 
Chromatography (TLC) results confirmed that amongst the tested strains, L. acidophilus 
NCFM was found to be the most efficient lactobacillus strain to utilize LNnT. In addition, we 
characterized the consumption of LNnT in L. acidophilus NCFM and further investigated a 
-galactosidase gene involved in LNnT utilization by L. acidophilus NCFM. β-galactosidase 
lacL gene knockout in L. acidophilus NCFM and subsequent carbohydrate utilization 
analysis demonstrated that LNnT was unable to be utilized by the knockout strain, 
confirmimg that β-galactosidase lacL gene is required for LNnT utilization. Additionally, 
growth curves of the lacL knockout strain showed a reduced growth rate and a longer lag 
phase on lactose, suggesting that the β-galactosidase lacL gene plays a significant role in 
LNnT and lactose utilization in L. acidophilus NCFM. 
In the third aim, the consumption of galactooligosaccharides (GOS) by lactobacilli 
was investigated by comparing with selected bifidobacteria in order to determine the 
metabolism of GOS, utilization patterns and potential of probiotic and prebiotic 
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combinations. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and 
TLC analysis of cell-free supernatants taken during growth of five probiotic bacteria 
suggested differences in the utilization of Purimune™ GOS (GOS-P). L. rhamnosus DR20 
and B. lactis Bb-12 preferentially utilized disaccharides, while L. fermentum and B. infantis 
utilized mostly di- and trisaccharides over larger degree of polymerization (DP) GOS. 
Among the tested strains, only L. acidophilus NCFM showed extracellular and intracellular 
β-galactosidase activity. Interestingly, L. acidophilus NCFM showed a preference to 
consume GOS with DP 2-6 and released galactose very efficiently from GOS-P. L. 
acidophilus NCFM lacL gene knockout and subsequent carbohydrate utilization analysis 
demonstrated that GOS was not utilized by the knockout strain, confirmimg that β-
galactosidase lacL gene is required for GOS utilization. Our results suggest that the -
galactosidase lacL gene is involved in GOS consumption by L. acidophilus NCFM, revealing 
that the role of functional lacL -galactosidase is important for the metabolism of lactose and 
complex carbohydrates for the survival of intestinal lactobacilli in GI tract.  
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CHAPTER 1 
 
OVERVIEW 
 
1.1 INTRODUCTION 
Human milk oligosaccharides (HMOs) represent the third most abundant component 
in human milk and have a degree of polymerization (DP) >3 (Newburg and Neubauer, 1995). 
However, due to previous difficulties and limitations in characterization of complex 
oligosaccharide structures and the lack of available individual substrate, little is known about 
their metabolism and utilization pathway in relevant micoorganisms.  Oligosaccharides in 
human milk possess natural prebiotic function and exert a protective role in breast-fed infants 
(Stevens et al., 2009; Use of prebiotic oligosaccharides in infant formula has been shown to 
be effective for formula-fed infants to develop the intestinal microbiota that is similar to 
breast-fed infants.  
Prebiotics are defined as food ingredients that fit to the three following criteria: 1) 
resistance to gastric acidity, to hydrolysis by mammalian enzymes, and to gastrointestinal 
absorption; 2) fermentation by intestinal microbiota; and 3) selective stimulation of the 
growth and/or activity of those intestinal bacteria that contribute to health and well-being 
(Roberfroid, 2007), in particular bifidobacteria. For this last reason, the world market for 
prebiotics has grown rapidly in the last three decades (Figueroa-Gonza et al., 2011), focusing 
on the production of compounds with established prebiotic effects (GOS, 
fructooligosaccharides (FOS), inulin, and lactulose), as well as development and 
commercialization of other dietary carbohydrates including resistant starch (Bird et al., 
2010), xylooligosaccharides (Jaskari et al., 1998), glucooligosaccharides (Djouzi et al., 1995; 
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Sarbani et al., 2011), polydextrose (Herfel et al., 2011), lactosucrose (Ohkusa et al., 1995), 
pectin derived (Gullon  et al., 2011) or soybean oligosaccharides (Hopkins et al., 1998). 
Lactobacilli belong to a group of Gram-positive facultative anaerobic or 
microaerophilic bacteria which are commonly found in the human GIT. These 
microorganisms are considered to be beneficial bacteria and help maintain a healthy GIT in 
adults.  L. acidophilus NCFM is a lactic acid bacterium that has the ability to survive in the 
GIT (Sanders and Klaenhammer, 2001; Sui et al., 2002), adhere to human epithelial cells in 
vitro (Sanders and Klaenhammer, 2001; Greene and Klaenhammer, 1994),  modify fecal 
flora (Sui et al., 2002),  modulate the host immune response and prevent microbial 
gastroenteritis (Varcoe et al., 2003). Additionally, L. acidophilus NCFM has the ability to use 
nondigestible oligosaccharides, which may also contribute to the organism’s ability to 
compete in the human GIT. 
 
1.2 RESEARCH OBJECTIVES  
The overall objective of this dissertation research was to characterize the 
consumption of HMOs, HMO precursors, and prebiotics by selected lactobacilli and 
bifidobacteria and further investigate a gene involved in HMO and prebiotic GOS utilization.  
Three specific aims were pursued. 
 
1.3 SPECIFIC AIMS 
Specific Aim 1 investigated the probiotic metabolism of human milk 
oligosaccharides (HMOs) and HMO precursors. In this study, we identified probiotics that 
can ferment HMOs and determined the growth characteristics of probiotics cultured on 
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sialylated and fucosylated HMO components (3’-SL, 6’-SL, 2’-FL and 3’-FL), nonsialylated/ 
nonfucosylated HMO (LNnT), and HMO precursors as reported in Chapter 3. 
 
Specific Aim 2 investigated the consumption of LNnT by selected lactobacilli and 
bifidobacteria. In order to understand the utilization of LNnT, a time course of LNnT 
degradation in L. acidophilus was characterized using High Performance Liquid 
Chromatography (HPLC) and Thin Layer Chromatography (TLC). In addition, data on the -
galactosidase gene (lacL) involved in LNnT utilization by L. acidophilus NCFM are 
summarized in Chapter 4. 
 
Specific Aim 3 determined the effect of GOS on the growth of probiotic 
bifidobacteria and lactobacilli. Data on Purimune GOS consumption profile and analysis of 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and thin layer 
chromatography (TLC) as well as -galactosidase activity, -galactosidase gene (lacL) 
involved in GOS utilization by L. acidophilus NCFM are reported in Chapter 5. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 PROBIOTICS 
A. Probiotics: Selection Criteria, Functions and Benefits 
According to the Food and Agriculture Organization of the United Nations and the 
World Health Organization, the term “probiotics” is defined as live microorganisms which 
when administered in sufficient amounts will have beneficial effects on the host health 
(FAO/WHO, 2002).  Recent comparative studies demonstrated that the probiotics and their 
health benefits are strain specific (Douillard et al., 2013). The diverse health benefits of 
probiotic bacteria may be due to various mechanisms of action and strain-specific properties 
of probiotics (Nagpal et al., 2012).   
A number of criteria are used to select for probiotic strains. An effective probiotic 
must be non-pathogenic and exert a beneficial effect on the host and be able to be produced 
industrially.  Additional potential properties relevant to probiotic activity include the 
following: i) capable of surviving passage through the GIT, ii) compete along with a highly-
diverse and competitive environment presented by the human gut microflora (Bezkorovainy, 
2001), iii) adhere to the intestinal epithelial cell lining (Guarner and Schaafama, 1998), iv) 
produce antimicrobial substances towards pathogens, v) remain viable during storage and 
use, and vii) be isolated from the same species as its intended use (Collin and Gibson, 1999). 
The functions of gut microbes as probiotics have been proposed, which rely on their ability to 
i) survive in the GIT, ii) adhere to mucosal surfaces , and iii) metabolize available energy 
sources from non-digestible dietary compounds (Qin et al., 2010). The health beneficial 
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effects of probiotic bacteria include i) improvement of intestinal health by regulation of 
microbiota, ii) stimulation and development of the immune system, iii) reduction of 
symptoms of lactose intolerance, and iv) prevention of certain other diseases such as allergies 
(Ozdemir et al., 2010) and colon cancer (Uccello et al., 2012).   
B. Microorganisms Considered as Probiotics  
The key organisms used for probiotics application worldwide belong to well-
characterized strains of Lactobacillus and Bifidobacterium which are available for human 
and animal use to reduce the risk of gastrointestinal infections or treat such infections 
(Salminen et al., 2005). Two other main species playing an important role in the food 
industry and dairy products are Streptococcus thermophilus and Lactococcus lactis. Some of 
the most important representative probiotic strains are listed in Table 2.1 (Kechagia et al., 
2013).  The most effective probiotic strains for human use have proved to be of human origin 
(Dunne et al., 2011).  The consumption of probiotics aim to directly supplement the intestinal 
microbiota with live beneficial organisms.  
Lactobacilli and bifidobacteria are common members of the human intestinal 
microbiota, and are nonpathogenic, nontoxigenic, nonputrefactive, saccharolytic organisms 
(Crittenden, 2004).  The probiotic potential of the intestinal and dairy species of lactobacilli 
and bifidobacteria was first researched over a hundred years ago. The link between 
lactobacilli and human health was first proposed in the late 1800s by Metchnikoff, who 
devoted the last decade of his life to this research. Lactobacillus species are members of 
lactic acid bacteria (LAB). LAB are Gram-positive, catalase-negative bacterial species that 
produce lactic acid as a primary metabolic end product.  A number of lactobacilli have been 
well characterized and used as probiotics including L. acidophilus. This bacterium was first 
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isolated by Moro in 1900 from infant feces. L. acidophilus NCFM is perhaps the most 
common L. acidophilus probiotic used commercially and has the ability to survive in the GIT 
(Sanders and Klaenhammer, 2001; Sui et al., 2002), adhere to human epithelial cells in vitro 
(Sanders and Klaenhammer, 2001; Greene and Klaenhammer, 1994), modify fecal flora (Sui 
et al., 2002), modulate the host immune response and prevent microbial gastroenteritis 
(Varcoe et al., 2003).  
Several genome sequences of microbial species isolated from the human GIT have 
been published including several LAB (Pridmore et al., 2004; Klaenhammer et al., 2002). 
The complete genome sequence of L. acidophilus NCFM encodes a large variety of genes 
related to carbohydrate utilization, including 20 phosphoenol-pyruvate sugar-transferase 
systems (PTS) and five ABC families of transporters potentially involved in the uptake and 
metabolism of a variety of carbohydrates (Altermann et al., 2005). It has been shown that a 
variety of L. acidophilus strains are able to utilize several polysaccharides and 
oligosaccharides (Kaplan et al., 2000; Van Laere et al., 2000). Additionally, L. acidophilus 
NCFM has the ability to utilize nondigestible oligosaccharides such as FOS and GOS 
(Barrangou et al., 2003). The predicted glycoside hydrolases encoded by its genome 
differentiate lactobacilli and bifidobacteria from most other bacteria that are typically found 
throughout the mammalian GIT (Gänzle and Follador, 2012; Altermann et al., 2005).  
A Bifidobacterium was first isolated and described from a breast-fed infant over a 
century ago and associated with a healthy intestinal tract due to numerical dominance in 
breast-fed infants and relation with reduced diarrhea symptoms compared to bottle-fed 
infants (Newburg, 2005). The traditional use of bifidobacteria in fermented dairy products 
and the Generally Recognized as Safe (GRAS) status of certain strains attest to their safety 
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(Picard et al., 2005). Whereas the function of bifidobacteria still remains somewhat 
enigmatic, clinical trials have led to their wide application aiming at improving host health, 
especially in fermented dairy products. They are also the target of prebiotic-containing 
products, typically oligosaccharides selectively fermented by bifidobacterial species. 
Although foods containing probiotic bifidobacteria and bifidogenic prebiotics are widely 
consumed, there is only fragmentary information about the physiology, ecology, and genetics 
of Bifidobacterium group members within the human host as well as on many isolated 
Bifidobacterium strains marketed as probiotics. 
C. Probiotic for Infant Nutrition  
Probiotic supplementation in infant formulas has shown that some strains may persist 
in the infant gut (Bennet et al., 1992; Millar et al., 1993) and lower stool pH (Langhendries et 
al., 1995).  Supplementation with L. casei sp. strain GG (Lactobacillus GG) fermented milk 
product or freeze dried powder, 125 g (10
10-11 
colony forming units, CFU) twice daily 
(Isolauri et al., 1991) and with Bifidobacterium bifidum (1.9x10
8 
CFU/g powdered formula) 
and Streptococcus thermophilus (0.1x10
8 
CFU/g powdered formula) (Saavedra et al., 1994) 
has been successful in preventing rotavirus diarrhea in infants. The LGG strain has also been 
well researched for its probiotic effects in reducing atopic eczema (Majamaa and Isolauri, 
1997; Kalliomäki et al., 2003). 
 Comparison of Intestinal Microbiota of Breast-Fed and Formula-Fed Infants 
The GIT of newborn is basically germ-free with the colonization of intestinal 
microbiota begins immediately after birth. Intestinal colonization by microorganisms has a 
pronounced impact on the maturation of the infant intestinal immune system and the gut 
microbiota is influenced by the feeding of the human infant. The first bacterial colonizers are 
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facultative Gram-positive cocci, enterobacteria and lactobacilli.  In breastfed infants, 
bifidobacteria constitute from 60-90% of the infant gut microbiota (Ip et al., 2007). In 
contrast, formula-fed infants have a more complex microbiota with bifidobacteria, 
bacteroides, lactobacilli, clostridia and streptococci (Stark and Lee, 1982; Benno et al., 1984; 
Harmsen et al., 2000).   
 
2.2 PREBIOTICS 
A. Prebiotics: Classification Criteria and Benefits 
Prebiotics have been defined as non-digestible dietary ingredients, usually 
oligosaccharides that selectively stimulate the growth or activity of a limited number of 
intestinal bacteria which results in providing a health benefit to the host (Gibson and 
Roberfroid, 1995). Due to the definition of prebiotics, the criteria for classification of food 
ingredients as prebiotics have been proposed which are  i) resistance to gastric acidity, 
hydrolysis by human enzymes and gastrointestinal absorption; ii) fermentation by intestinal 
microbiota; and iii) selective stimulation of the growth and/or metabolic activity of beneficial 
bacteria in GIT (Roberfroid, 2007). Currently, the research on prebiotics and the most 
common commercially available prebiotics that fulfill those criteria include inulin, FOS, and 
GOS (Rastal, 2010).  
The development of  the microbiota is affected by various external and internal 
factors. Diet is one of the external factors that influence the development of the intestinal 
microbiota. Human milk oligosaccharides (HMOs) are likely to be one of the factors that 
influence the development of microbiota in breast-fed infants and protect infants from 
microbial infections or other diseases. In an attempt to simulate the effect of breast feeding in 
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formula-fed infants, oligosaccharides have been supplemented in infant formula as 
prebiotics. The prebiotic effects of these oligosaccharides have been evaluated by many 
clinical studies. Application of various techniques to the analysis of intestinal microbiota has 
led to the better understanding of the structure and development of infant intestinal 
microbiota and a reevaluation of the effects of prebiotics in infant formula. 
B. Prebiotics in Infant Nutrition      
The oligosaccharides in human milk are considered to possess natural prebiotic 
function and appear to play a protective role in the breast-fed infants. Use of prebiotic 
oligosaccharides in infant formula has been shown to be effective for the formula-fed infants 
to develop the intestinal microbiota which is similar to breast-fed infants.  These strategies 
will be discussed below. The supplementation of infant formula with 0.8 g/100 ml GOS/FOS 
in a 9 to 1 ratio stimulates the number of fecal bifidobacteria; B. infantis, B. breve and B. 
longum. After a 6-week intervention period, the results showed a significant increase in the 
total amount of fecal bifidobacteria (54.8% + 9.8% to 73.4% + 4.0%) in infants receiving the 
prebiotic formula, with a diversity of Bifidobacterium species similar to breast-fed infants  
(Haarman and Knol, 2005; Roberfroid, 2007).  
Feeding infant formula supplemented with GOS and long chain FOS (lcFOS) (1:9) 
significantly increased the number of bifidobacteria accompanied by a reduction of 
pathogens in both preterm infants and term infants (Boehm et al., 2002; Kolida et al., 2002; 
Knol et al., 2005). Previous studies have shown that supplementing preterm formula with a 
mixture of GOS and FOS at a concentration of 10 g/l stimulates the growth of bifidobacteria 
in the intestine and results in stool characteristics similar to those found in preterm infants 
fed human milk (Boehm et al., 2002). Bifidobacteria in the group fed the oligosaccharide 
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supplemented formula increased to the upper range of bifidobacteria counts in the reference 
group. The difference between the supplemented and non-supplemented groups was highly 
significant (p = 0.0008).   
The GOS/FOS supplement caused the microbial diversity to closely resemble the 
microbiota of breast-fed infants, also at the level of the different Bifidobacterium species. 
Differences in percentage of bifidobacteria between the GOS/FOS (59.2% (SEM 7.7)), Bb-
12 (52.7% (SEM 8.0)) and the standard (51.8% (SEM 6.4)) groups were not statistically 
significant at 16 weeks. Feeding infants GOS/FOS formula resulted in a similar effect on 
metabolic activity of the intestinal microbiota as in breast-fed infants (Bakker-Zierikzee, 
2005).  Moreover, Haarman and Knol conducted a study that showed a significant increase in 
the total amount of fecal bifidobacteria (54.8% + 9.8% to 73.4% + 4.0%) in infants receiving 
the prebiotic formula (a standard formula supplemented with galacto- and fructo-
oligosaccharides, OSF) with a diversity of Bifidobacterium species similar to breast-fed 
infants (Haarman and Knol, 2005).  
C. Prebiotic Galactooligosaccharide (GOS) 
GOS have a GRAS status in the United States, a non-Novel Food status in the EU, 
and are regarded as foods for specific health use (FOSHU) in Japan, (Tzortzis and Vulevic 
2009) due to the fact that GOS are components of human milk and traditional yogurt and can 
be produced from ingested lactose by the resident intestinal bacteria. Commercial GOS are 
typically produced by enzymatic synthesis/transgalactosylation of lactose to yield a mixed-
length galactosylated product with a degree of polymerization (DP) ranging from 2 to 6 
(Figure 2.1). The oligomeric nature and β-galactoside linkages allow GOS to be used as 
prebiotic supplements, notably for stimulation of lactobacilli and bifidobacteria in particular. 
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D. Human Milk Oligosaccharides (HMOs)   
Human milk is considered as the gold standard of infant nutrition, with commercially 
available infant formula designed to mimic its unique composition. However there is a need to 
provide safe and effective alternative forms of nutrition to infants who do not receive breast milk. 
Breastfeeding has several protective mechanisms and positive effects on the infant that are not 
replicated by components in infant formula, such as disease prevention including painful ear 
infections, upper and lower respiratory ailments, allergies, intestinal disorders, colds, viruses, 
and increased vaccination response (Dorea, 2009). Young infants need adequate levels of 
nutrition to support the development of their GIT and immune systems. Manipulating the 
composition of formula, by adding functional ingredients could improve the development of the 
immune and GIT in formula fed neonates. 
 Human Milk Oligosaccharide Composition  
HMOs are the third most abundant component of human milk which are typically 
found at 5-15 g/l in mature milk (Kunz et al., 2000; Bode, 2009; Zivkovic et al., 2011) 
(Figure 2.2).  The monosaccharide building blocks of HMOs are D-glucose, D-galactose, N-
acetyl-D-glucosamine (GlcNAc), L-fucose and sialic acid. Approximately 200 different 
oligosaccharide compositions have been identified in human milk (Bode, 2009).  The 
composition of mature human and bovine milk is compared in Table 2.2 
Lactose forms the reducing ends of the HMOs and lactose can be fucosylated 
on the nonreducing end in α1-2 and α1-3 linkages to form 2'-fucosyllactose (2'-FL) and 3'-
fucosyllactose (3'-FL), respectively. Lactose can also be sialylated on the nonreducing end in 
α2-3 and/ or α2-6 linkages to form 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), 
respectively. More complex HMOs can be produced by different combinations of the five 
monosaccharides listed above. HMOs are synthesized by the glycosyltransferase-catalyzed 
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transfer of monosaccharides from sugar nucleotides to elongating carbohydrate structures. 
Lactose is used as the basis for the synthesis of larger and more complex structures. These 
larger structures are synthesized by fucosyltransferases, which only certain women have. 
HMOs vary among individuals because they are associated with the same genes that 
determine Lewis blood type and secretor status (Viverge et al., 1990). Reported 
concentrations of individual HMOs in human milk are shown in Table 2.3. The structures of 
major oligosaccharides in human milk are shown in Table 2.4. Oligosaccharides are resistant 
to digestion and, thus, remain intact until reaching the large intestine, which allows them to 
have many functions throughout the intestinal tract. 
Several beneficial activities have been attributed to HMOs including  
immunomodulation of the host (Kuntz et al., 2008; Kuntz et al., 2009) and prevention of 
pathogen attachment (Bode, 2009).  In addition, it has been postulated that the bifidogenic 
nature of human milk is due to prebiotic activities of HMOs (Bode and Jantscher-Krenn 
2012; Sela and Mills, 2010).  HMOs appear to be resistant to host hydrolases in the small 
intestine and reach the large intestine largely intact (Engfer et al., 2000).  Recently, there 
have been reports of selected bifidobacteria strains, specifically Bifidobacterium infantis, 
being able to ferment HMOs (Ward et al., 2006; LoCascio et al., 2007; Marcobal et al., 2010; 
Zivkovic et al., 2011).  
 Type 1 and Type 2 Human Milk Oligosaccharides  
HMOs have been structurally classified into 13 core structures (Table 2.5) with all 
possessing a lactose unit at the reducing end (Urashima et al., 2012; Amano et al., 2009; 
Kobata, 2010). An additional categorization of HMOs is based on the disaccharide unit at the 
non-reducing end into type 1 and type 2.  In human milk, type 1 oligosaccharides are 
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predominant and type 2 oligosaccharides are less abundant (Kitaoka, 2012). In N-glycans, O-
glycans, and glycolipids structure, N-acetyl-D-glucosamine (GlcNAc) residues can be 
modified by galactose in β1-3 linkage to obtain a type 1 oligosaccharide composed of a 
disaccharide called neo-N-acetyllactosamine (Figure 2.3). In humans, expression of type 1 
oligosaccharide is mostly restricted to the epithelia of the GIT. Type 1 oligosaccharide can be 
modified by glycosyltransferases that transfer sugars to terminal galactose or subterminal 
GlcNAc, generating sialylated and fucosylated structures. The synthesis of type 1 
oligosaccharide and expression of the corresponding β1-3 galactosyltransferases are 
regulated in certain mammalian tissues. The addition of galactose in β1-4 linkage with 
GlcNAc creates a type 2 oligosaccharide, which is composed of the disaccharide Galβ1-
4GlcNAc, called N-acetyllactosamine (LacNAc, LN) (Figure 2.3). Similar to type 1 
oligosaccharides, the terminal galactose can be further modified by the transfer of an 
additional GlcNAc residue, which in turn receives a galactose in β1-4 linkage, thus forming 
two LacNAc units.  
Recent studies on the structures of oligosaccharides in human milk or colostrum have 
determined that type 1 oligosaccharides such as LNT, LNFP I, or LNDFH I are more 
abundant, as a group, than type 2 oligosaccharides such as LNnT or LNFP III (Urashima et 
al., 2012; Thurl et al., 2010). Of these two types, the most abundant oligosaccharides (17%) 
(Figure 2.2) in HMOs are LNT [Lacto-N-tetraose, Gal(β1-3)GlcNAc(β1-3)Gal(β1-4)Glc] 
and LNnT [Lacto-N-neotetraose, Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc] (Ninonuevo et al., 
2006; Wu et al., 2010; Zivkovic et al., 2011) . The difference between these two structures is 
the linkage between a terminal galactose and N-acetyl-D-glucosamine (Aldredge et al., 
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2013). Where LNnT contains a terminal 1-4 linkage, LNT contains a terminal 1-3linkage 
(Table 2.6).  
 
2.3. CARBOHYDRATE UTILIZATION 
A. Carbohydrate Utilization by Lactic Acid Bacteria 
Undigested carbohydrates are a primary source of energy for intestinal microbes 
residing in the large intestine. Nondigestible oligosaccharides (NDOs) consist primarily of 
plant carbohydrates that are resistant to enzymatic degradation and are not absorbed in the 
upper GIT. Such dietary compounds eventually reach the large intestine. As a result, NDOs 
have the ability to selectively modulate the composition of the intestinal microflora (Sui et 
al., 2002). NDOs, such as raffinose and FOS, have been shown to selectively promote the 
growth of probiotic species and are considered prebiotic compounds (Benno et al., 1987; 
Gibson et al., 1995). Although considerable attention has been devoted to studying 
modulation of the intestinal flora by prebiotics, the molecular mechanisms involved in uptake 
and metabolism of those compounds by desirable intestinal microbes remains mostly 
uncharacterized. 
Lactic acid bacteria can use a variety of nutrients. Specifically, the genomes of 
lactobacilli and streptococci encode specialized saccharolytic machinery that reflects the 
nutrient availability in their respective environments (Ajdic et al., 2002; Klaenhammer et al., 
2005; Kleerebezem et al., 2003, Pridmore et al., 2004). In particular, the saccharolytic 
potential of L. acidophilus likely reflects its ability to efficiently use energy sources available 
in the intestinal environment. Although the L. acidophilus NCFM genome encodes numerous 
putative genes potentially involved in the uptake and metabolism of a variety of 
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carbohydrates (Altermann et al., 2005), little information is available regarding their specific 
biological functions and expression profiles. 
B. Metabolism of Human Milk Oligosaccharides (HMOs)  
 Utilization of Type 1 and Type 2 Oligosaccharide                                                            
Several studies have investigated the ability of bifidobacteria to assimilate type 1 and 
type 2 HMOs (Yoshida et al., 2012; Miwa et al., 2010; Wada et al., 2008) (Figure 2.4) which 
will be described below. However, the fermentation of type 1 and type 2 oligosaccharides by 
lactobacilli has not been characterized. 
 Utilization of Lacto-N-tetraose (Type 1 Structure) 
The metabolic pathway of LNT in bifidobacteria was previously identified (Wada et 
al., 2008). In this pathway, LNT is hydrolyzed into Galβ1-3GlcNAc (lacto-N-biose I, LNB) 
and lactose by extracellular lacto-N-biosidase (Figure 2.4A). Lacto-N-biose I is then 
incorporated into bifidobacterial cells through a specific ATP binding cassette (ABC) 
transporter (Suzuki et al., 2008; Wada et al., 2007) and metabolized by intracellular enzymes. 
Consequently, LNB-I selectively promoted the growth of several bifidobacteria in vitro 
(Kiyohara et al., 2009).  In addition, Wada and colleagues were able to find Lacto-N-
biosidase activity in several bifidobacteria but were unable to find this activity in any other 
enteric bacteria tested including clostridia, bacteroides and lactobacilli that were tested 
(Wada et al., 2008). 
 Utilization of Lacto-N-neotetraose (Type 2 Structure) 
Miwa and colleagues identified a gene encoding extracellular β-galactosidase and 
extracellular β-N-acetylhexosaminidase from B. bifidum JCM1254 (Miwa et al., 2010)  
(Figure 2.4B). LNnT was sequentially fermented extracellularly by these enzymes from the 
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non-reducing end. In contrast to the metabolic pathway specific for LNnT in bifidobacteria, 
in lactobacilli the pathway has not yet been investigated. In fact, we were unable to find any 
publications that have identified β-N-acetylhexosaminidase activity in lactobacilli.  Our 
bioinformatic analysis has identified candidates for this gene in the genomes of a few 
lactobacilli. Thus, studying the occurrence of enzyme releasing LNTri in lactobacilli is 
important, not only for a better understanding of the LNnT/LNTri pathway, but also for 
elucidating the degradation pathway of HMOs with a type 2 structure. 
C. HMO Consumption by Bifidobacteria 
Some of the health benefits attributed to bifidobacteria can be explained by their 
unique sugar metabolism. Due to strain heterogeneity and taxonomic confusion (Mattarelli et 
al., 2008) within the genera, it is very difficult to generalize the mechanism of HMO 
catabolism across bifidobacteria. The most common infant-borne bifidobacteria, B. bifidum, 
B. longum subsp. infantis, and B. breve, possess different modes for consumption of HMO 
(Figure 2.5). B. longum subsp. infantis import lower molecular-weight HMO via specific 
soluble binding proteins and transporters, followed by intracellular catabolism by a 
complement of glycosidases before entry of the monosaccharides into central metabolic 
pathways. While B. bifidum exports fucosidases and lacto-N-biosidase for extracellular 
hydrolysis to remove LNB from the HMO structure, internalizes the free LNB, and 
catabolizes it intracellularly. B. breve consumes the various monomer constituents of HMO, 
imports them as monosaccharides, followed by intracellular catabolism (Zivkovic et al., 
2011). These different strategies suggest a possible mechanism for niche partitioning among 
the different bifidobacteria species within the developing infant GIT microbiota. 
 
17 
 
D. Metabolism of Prebiotic GOS by Lactobacilli and Bifidobacteria 
Stimulation of Bifidobacterium and Lactobacillus species by prebiotic 
oligosaccharides, including GOS, is well documented by observational studies (Moro et al., 
2002; Vulevic et al., 2008; Davis et al., 2010; Drakoularakou et al., 2010). However, only 
few studies have confirmed the lactobacilli enrichment by GOS on the strain level. Bacterial 
consumption of GOS requires transport molecules and specific glycosyl hydrolases that can 
release galactose to be used in central metabolic pathways. GOS transporter was first 
identified in the Lactobacillus genus suggesting that the lactose permease (lacS) is capable of 
transporting oligosaccharides such as GOS with a DP of >2-6 and modified disaccharides 
(lactitol) (Andersen et al., 2011). Additionally, lacS was reported as the sole transporter for 
lactose, GOS and lactitol in L. acidophilus NCFM.  Analysis of the adjacent genes of lacS 
showed three core genes: lacS, lacR, and β-galactosidase of either GH2 (lacZ or lacLM) or 
GH42 (lacA) family.  
Garrido and colleagues characterized consumption of Purimune GOS in B. infantis 
isolates from infant feces and investigated the mechanisms involved in GOS degradation and 
metabolism in B. infantis ATCC 15697. They observed that all B. infantis isolates can grow 
on GOS with DP up to 3, and some isolates showed a significant consumption of larger GOS.  
B. infantis ATCC 15697 has five genes encoding -galactosidases, and three of them 
(Blon_0268, Blon_2334 and Blon_2416) were induced during bacterial growth on GOS. In 
addition, Blon_2016 showed a significant activity against several galactosyl linkages and 
releasing galactose from GOS which contains 1-3, 1-4 and 1-6 galactosyl linkages. 
Overall these studies provide the evidence for GOS consumption and also represent the 
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physiological differences in the metabolism of prebiotics that may have a different impact on 
the host (Garrido et al., 2013). 
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2.4 TABLES AND FIGURES 
Table 2.1 Microorganisms considered as probiotics (adapted from Kechagia et al., 2013) 
Microorganisms considered as probiotics 
Lactobacillus species Bifidobacterium species Other lactic acid bacteria Non-lactic acid bacteria 
L. acidophilus  B. adolescentis Enterococcus faecalis Bacillus cereus var. toyoi 
L. casei B. animalis E. faecium Escherichiacoli strain nissle 
L. crispatus B. bifidum Lactococcus lactis Propionibacterium freudenreichii 
L. gallinarum B. breve Leuconostoc mesenteroides Saccharomyces cerevisiae 
L. gasseri B. infantis Pediococcus acidilactici S. boulardii 
L. johnsonii B. lactis Sporolactobacillus inulinus 
 L. paracasei B. lonngum Streptococcus thermophilus 
 L. plantarum 
   L. reuteri 
   L. rhamnosus       
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Table 2.2 Comparison of macronutrients and oligosaccharides in human and bovine milk 
 
  Human Bovine 
Protein (g/l) 8
a
 32
a
 
Fat (g/l) 41
a
 37
a
 
Lactose (g/l) 70
a
 48
a
 
Oligosaccharides (g/l) 5-15
b
 0.05
c
 
Number of identified oligosaccharides  100+
b,d
 ~40
e
 
% Fucosylated 50-80
b,d,,f
 ~1%
e
 
% Sialated 10-20
b,d
 ~70%
e
 
 
a
Data from Hale and Hartmann (2007). 
b
Data compiled from the following references: Coppa et al. (1999), Kunz et al. (1999). 
Newburg et al. (2000), Davidson et al. (2004), Bao et al. (2007) and Gabrielli et al. (2011). 
c
Data from Gopal and Gill. (2000). 
d
Data complied from the following references: Ninonuevo et al. (2006) and Wu et al. (2010)  
and reviewed in Kobata (2010). 
e
Data from Tao et al. (2008; 2009). 
fDepending on the woman’s Se/Le blood group status. 
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Table 2.3 Major composition and content of oligosaccharides in human milk 
 
Human milk oligosaccharides (HMOs) Average (g/l) Concentration (g/l) Citation 
2'-Fucosyllactose (2'-FL) 2.7 2.4-4.9 Musumeci et al., 2006 
  
2.60 Thurl et al., 2010 
  
2.43 Chaturvedi et al., 2001 
  
2.03 Asakuma et al., 2008 
  
1.88 Newburg et al., 2004 
3'-Fucosyllactose (3'-FL) 0.5 0.86 Chaturvedi et al., 2001 
  
0.79 Thurl et al., 2010 
  
0.28 Newburg et al., 2004 
    0.25 Asakuma et al., 2008 
3'-Sialyllactose (3'-SL) 0.2 0.1-0.3 Kunz et al., 2000 
  
0.1-0.3 Martin-Sosa et al., 2003 
  
0.27 Thurl et al., 2010 
  
0.07 Bao et al., 2007 
6'-Sialyllactose (6'-SL) 0.5 1.22 Thurl et al., 2010 
  
0.3-0.5 Kunz et al., 2000 
  
0.2-0.3 Martin-Sosa et al., 2003 
    0.29 Bao et al., 2007 
Lacto-N-neotetraose (LNnT) 0.3 0.45 Asakuma et al., 2008 
  
0.30 Newburg et al., 2004 
  
0.25 Thurl et al., 2010 
    0.17 Chaturvedi et al., 2001 
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Table 2.4 Structure of major oligosaccharides in human milk (adapted from Aldredge et al., 2013) 
 
 
a2’-FL: 2’-Fucosyllactose; b3’-FL: 3’-Fucosyllactose; c3’-SL: 3’Sialyllactose; d6’-SL: 6’-Sialyllactose;                                                  
e
LNnT: Lacto-N-neotetraose; 
f
LNT: Lacto-N-tetraose 
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Table 2.5 The 13 core structures in human milk oligosaccharides (Urashima et al., 2012) 
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Table 2.6 Type 1 and type 2 oligosaccharides (adapted from Urashima et al., 2012) 
Oligosaccharides Name Structure 
Type 1 Oligosaccharides LNT
 a
  Gal(β1-3)GlcNAc(β1-3)Gal(β1-4)Glc 
 
LNFP I
 b
 Fuc(α1-2)Gal(β1-3)GlcNAc(β1-3)Gal(β1-4)Glc 
 
LNFP II
 c
 Gal(β1-3)Fuc(α1-4)GlcNAc(β1-3)Gal(β1-4)Glc 
 
LNDFH I
 d
 Fuc(α1-2)Gal(β1-3)Fuc(α1-4)GlcNAc(β1-3)Gal(β1-4)Glc 
Type 2 Oligosaccharides LNnT
 e
 Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc 
  LNFP III
 f
 Gal(β1-4)[Fuc(β1-3)]GlcNAc(β1-3)Gal(β1-4)Glc 
a
LNT: Lacto-N-tetraose;  
b
LNFP I: Lacto-N-fucopentaose I; 
c
 LNFP II: Lacto-N-fucopentaose II; 
d
 LNDFH I:
:  
                                         
Lacto-N-difucohexaose I; 
e
 LNnT: Lacto-N-neotetraose; 
f
 LNFP III: 
 
Lacto-N-fucopentaose III.
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Table 2.7 Mode of sugar fermentation in Lactobacillus species (Barrangou et al., 2012) 
Homofermentative Facultative Heterofermentative Obligatory Heterofermentative 
L. acidophilus L. casei L. brevis 
L. delbrueckii L. curvatus L. bunchneri 
L. helveticas L. plantarum L. fermentum 
L. salivarius L. sakei L. reuteri 
    L. pontis 
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Figure 2.1 Commercial β-galactooligosaccharides (GOS) are typically produced by 
enzymatic synthesis/transgalactosylation of lactose to yield a mixed-length galactosylated 
product with a degree of polymerization (DP) ranging from 2 to 6. 
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Figure 2.2 Human milk composition (adapted from Zivkovic et al., 2011). MSMFLNnH: 
Monosialyl, monofucosyllacto-N-neohexaose; LNFP I: Lacto-N-fucopentaose I; LNFP II: 
Lacto-N-fucopentaose II; LNFP III: Lacto-N-fucopentaose III; LNFP V: Lacto-N-
fucopentaose V; LNT: Lacto-N-tetraose; LNnT: Lacto-N-neotetraose; MFLNHI: 
Monofucosyllacto-N-hexaose I; MFLNHIII: Monofucosyllacto-N-hexaose III; MFpLNH IV: 
Monofucosyl-para-lacto-N-hexaose IV; IFLNH I: isomer 1 fucosyl-paralacto-N-hexaose; 
IFLNH III, isomer 3 fucosyl-paralacto-N-hexaose. 
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Figure 2.3 Modification of type 1 and type 2 oligosaccharides. Terminal N-acetyl-D-
glucosamine (GlcNAc) residues are usually galactosylated. Modification by β1-4Gal residues 
(top) occurs in all mammalian tissues. This reaction is catalyzed by β1-4 
galactosyltransferase (β1-4GalT) and yields the Galβ1-4GlcNAc (N-acetyllactosamine) unit 
termed type 2. Transfer of β1-3Gal residues (bottom) is restricted to certain tissues. This 
reaction is catalyzed by β1-3 galactosyltransferase (β1-3GalT) and yields the Galβ1-
3GlcNAc (neo-N-acetyllactosamine) unit termed type 1. Type 1 and type 2 oligosaccharides 
can be further modified by subsequent glycosylation reactions. Poly-N-acetyllactosamine 
chain initiation is also shown. LN, N-acetyllactosamine unit; Lac, Lactose; LNT, Lacto-N-
tetraose; LNnT, Lacto-N-neotetraose  (adapted from Stanley and Cummings, 2008). 
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Figure 2.4 Pathway of the extracellular enzymatic hydrolysis of LNT (A) and LNnT (B) by                   
B. bifidum. Lac, Lactose; LNT, Lacto-N-tetraose; LNnT, Lacto-N-neotetraose; LNB, Lacto-N-
biose I; LNTri, Lacto-N-triose (adapted from Kitaoka et al., 2012). 
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Figure 2.5 Strain-specific strategies for human milk oligosaccharides import and catabolism 
by bifidobacteria. Glc, Glucose; Gal, Galactose; GlcNAc, N-acetyl-D-glucosamine; Fuc, L-
Fucose (Adapted from Zivkovic et al., 2011). 
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CHAPTER 3 
PROBIOTIC METABOLISM OF 
HUMAN MILK OLIGOSACCHARIDES (HMOs) 
 
3.1 ABSTRACT 
Human milk contains a high concentration of complex oligosaccharides (HMOs) that 
are believed to confer physiological benefits to infants such as immunomodulation and 
prevention of pathogen attachment. In addition, it has been postulated that HMOs serve as 
prebiotics by promoting the growth of bifidobacteria in the infant gastrointestinal tract (GIT). 
In this study, growth parameters were determined by inoculating glucose-grown cultures into 
basal deMan Rogosa Sharpe (MRS) (no added glucose) with 1% carbohydrate (+0.5 g/l L-
cysteine for bifidobacteria) and measuring growth over 48 h.  Cultures were grown in 
microtiter plates which were incubated under 90% N2, 5% CO2 and 5% H2 at 37
o
C.  Results 
indicated that: (1) N-acetyl-D-glucosamine (GlcNAc) was widely used by the lactobacilli, but 
B. breve ATCC15700 was the only bifidobacteria strain that could utilize this carbohydrate, 
(2) none of the bifidobacteria and very few lactobacilli could utilize either free L-fucose  (L. 
rhamnosus GG and L. rhamnosus DR20) or sialic acid (L. plantarum LP‐66), (3) none of the 
lactobacilli could ferment the HMOs: 3'-Sialyllactose (3’-SL), 6'-Sialyllactose (6’-SL), 2’-
Fucosyllactose (2’-FL) and 3’-Fucosyllactose (3’-FL), yet four lactobacilli demonstrated 
moderate growth with Lacto-N-neotetraose (LNnT), (4) amongst the bifidobacteria strains, 
only   B. infantis ATCC 15697 and B. infantis M-63 were able to ferment 3’SL, 6’SL, 2’-FL 
and 3’-FL, (5) when B. infantis M‐63 was grown with 3’-SL, no sialic acid accumulated in 
the growth media, but when it was grown with 2’-FL, 44% of the L‐fucose liberated from 2’-
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FL remained in the media and (6) B. infantis, B. breve, L. acidophilus, L. plantarum and L. 
reuteri were able to ferment LNnT, which was confirmed by high performance liquid 
chromatography (HPLC) analysis.  Our results demonstrated that there are differences in 
metabolisms of milk oligosaccharides among lactobacilli and bifidobacteria strains, 
information that may aid in the development of future synbiotic formulations. 
 
3.2 INTRODUCTION 
Human milk contains all of the essential nutrients required for the growth and 
development of infants.  The third most abundant component of human milk is human milk 
oligosaccharides (HMOs) which are typically found at 5-10 g/L in mature milk (Bode, 2009).  
HMOs consist of linear and branched polymers of glucose, galactose, GlcNAc, L-fucose and 
sialic acid.   Approximately 200 different oligosaccharides have been identified in human 
milk (Bode, 2009).  Several beneficial activities have been attributed to HMOs including 
immunomodulation of the host (Kuntz et al., 2009; Kuntz et al., 2008) and prevention of 
pathogen attachment (Bode, 2009).  In addition, it has been postulated that the bifidogenic 
nature of human milk is due to prebiotic activities of HMOs (Sela and Mills, 2010).  HMOs 
appear to be resistant to host hydrolases in the small intestine and likely reach the large 
intestine largely intact.  Recently, there have been reports of selected bifidobacteria strains, 
specifically Bifidobacterium infantis, being able to ferment HMOs (Zivkovic et al., 2010; 
Marcobal et al., 2010; Ward et al., 2006; LoCascio et al., 2007).   
Herein, probiotic fermentation parameters were determined for purified HMOs, HMO 
precursors and prebiotics.  Semi-synthetic carbohydrate-free media, sMRS (lactobacilli) and 
sMRS supplemented with 0.5g/l (wt/vol) L-cysteine (bifidobacteria), support minimal growth 
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of the probiotics without the addition of carbohydrate.  Consequently, the ability to ferment a 
carbohydrate can be determined by calculating the growth parameters of the probiotic in 
sMRS plus the selected carbohydrate.  Maximum optical density at 600 nm (OD600),           
∆OD600, specific growth rate, doubling time and lag time were calculated from anaerobic 
growth curves for each probiotic after the addition of carbohydrate to the basal media.  Our 
results identify numerous strain differences amongst the tested probiotics which will aid the 
development of future synbiotic infant formulas.   
 
3.3 MATERIALS AND METHODS 
Bacterial Cultures                     
All lactobacilli strains were initially inoculated from frozen stocks and grown in MRS 
broth (Difco, Detroit, MI, USA) and incubated at 37°C for 24 h in an anaerobic chamber 
(90% N2, 5% CO2 and 5% H2; Coy Laboratory Products, Grass Lake, MI, USA).  
Subsequently, the cultures were passed twice on a semi-synthetic MRS medium  (Barrangou 
et al., 2003) which was supplemented with 1% (wt/vol) filter-sterilized glucose as the sole 
carbohydrate source.  After the second pass, cultures were prepared to use as inoculums for 
growth assays described below.  For bifidobacteria strains, the same procedure was followed 
except all media were supplemented with 0.05% (wt/vol) L-cysteine.  All bacterial strains 
used for this study are listed in Table 3.1.  In total, 12 lactobacilli and 12 bifidobacteria 
strains were tested.  
Bacterial Growth Assays 
After the second pass in sMRS supplemented with glucose, the cultures were washed 
2X with 10 ml of sterile sMRS lacking carbohydrate, resuspended in 10 ml of sterile sMRS 
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lacking carbohydrate and then used as a 1% inoculum for the growth study.  Carbohydrates 
used for this study (Table 3.2) were sterilized with a 0.22 micron filter and used at a 1% final 
concentration.  Cell growth was performed in 250 l of sMRS (supplemented with 0.05% 
(wt/vol) L-cysteine for bifidobacteria) covered with 50 l of mineral oil in a Bioscreen 100-
well honeycomb plate (Growth Curves USA, Piscataway, NJ, USA).  Cell growth was 
monitored by measuring OD600. The Bioscreen C machine placed in a Coy anaerobic 
chamber was operated in discontinuous mode, with absorbance readings performed in 30 min 
intervals, and preceded by 30s shaking intervals at maximum speed.  Controls consisted of 
inoculated medium lacking carbohydrate and uninoculated medium was used as a blank. On 
the microtitre plate, the carbohydrates were divided into two separate groups:  group A 
(HMO precursors: glucose, galactose, lactose, GlcNAc, L-fucose, fructose and sialic acid) 
and group B (HMOs: glucose, 3’-SL, 6’-SL, 2’-FL, 3’-FL and Lacto-N-neotetraose (LNnT).  
All plates included a positive control containing glucose and negative control lacking 
carbohydrate. 
Kinetic Analysis of Bacterial Growth 
The OD600 data for each carbohydrate was corrected by subtracting the OD600 of the 
basal media (sMRS) from the sample plate for each probiotic.  Maximum OD600 was 
determined by inspection of the corrected growth data.  ∆OD600 was determined by 
subtracting the initial corrected OD600 (timepoint 0) from the maximum corrected OD600.  
Maximum specific growth rate (max), lag time (tlag) and doubling time (td) were calculated 
using algorithms written in Matlab (Matlab, The Mathworks Inc., Natick, MA, USA) only for 
samples that had a ∆OD600 greater than 0.25.  Specific max was determined by measuring 
the slope of 1 and 2 hour intervals of the growth curve and reporting the maximum specific 
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growth rate.  For growth curves with steep log-phases, a 1 hour interval is appropriate.  For 
growth curves with shallow log-phases, a 2 hour interval is appropriate.  Doubling time was 
calculated using the specific growth rate for both intervals.  The lag time is calculated by 
using the point-slope form (y-y1=m(x-x1) with the maximum specific growth rate as the 
slope.   Samples were grown in biologically independent triplicates and the resulting growth 
kinetic data were expressed as the mean of these replicates (Appendix A). For the growth 
curve plots, OD600 and time was first plotted for the bacteria grown on medium lacking 
carbohydrate (sMRS).  For all other carbohydrates, the OD600 data was corrected by 
subtracting the OD600 of sMRS.   
HMO Fermentation 
Co-culture studies 
To examine the potential for metabolic cross-feeding for B. longum subsp. infantis M-
63 which is able to utilize 3’-SL or 2’-FL as growth substrates yet could not ferment sialic 
acid or L-fucose.  For 3’-SL, the following five treatment groups were used:  (1) B. infantis 
M-63; (2) L. plantarum LP-66; (3) B. infantis M-63 and L. plantarum LP-66; (4) 
uninoculated medium containing 3’-SL, and (5) B. infantis M-63 and L. plantarum LP-66 
lacking 3’-SL. The incubation was done in 3 ml of sMRS supplemented with 0.05% (wt/vol) 
L-cysteine and 1% (wt/vol) 3’-SL for 72 h. For 2’-FL, the following treatments were used: 
(1) B. infantis M-63 and (2) uninoculated medium containing 2’-FL.  In this case, the 
incubation was done in 250 l of sMRS supplemented with 0.05% (wt/vol) L-cysteine and 
1% (wt/vol) 2’-FL for 48 h. 
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Analytical methods 
For the analysis of HMO consumption, the post fermentations (250 l) were taken at 
the indicated times and centrifuged at 12,000 x g for 5 min at room temperature, and the 
resulting supernatants were immediately stored at -20°C until further analysis. Changes in 3’-
SL, 2’-FL and LNnT concentrations after fermentation were determined by HPLC (Agilent 
Technologies 1200 Series) equipped with a refractive index detector using a Rezex ROA-
Organic Acid H
+
 (8%) column (Phenomenex Inc.). The column was eluted with 0.005 N of 
H2SO4 at a flow rate of 0.6 mL∕min at 50°C (Ha et al., 2011). 
 
3.4 RESULTS 
HMO Precursor Fermentation 
All bifidobacteria tested grew very little in the basal media (sMRS supplemented with 
0.5 g/l (wt/vol) L-cysteine) whereas they all grew well in glucose (Table 3.3).  In general, the 
bifidobacteria which could not ferment galactose also had reduced growth on lactose.  None 
of the bifidobacteria could ferment L-fucose or sialic acid, two key constituents of HMOs 
and mucin.  Only B. breve ATCC 15700 could ferment GlcNAc, a key component of HMOs 
and mucin.  Lastly, the majority of bifidobacteria could ferment fructose.   
Similar to bifidobacteria, all lactobacilli grew minimally in the basal media (sMRS) 
whereas they all grew well in glucose (Table 3.4). All lactobacilli could ferment galactose, 
except for L. acidophilus NCFM.  All lactobacilli, except L. rhamnosus GG and L. jensenii 
ATCC 25258, could ferment lactose.  Only L. rhamnosus GG and L. rhamnosus DR20 could 
ferment L-fucose and only L. plantarum LP-66 could ferment sialic acid.  All lactobacilli 
could ferment GlcNAc, except for L. reuteri.   
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HMO Fermentation  
As predicted based on the literature (LoCascio et al., 2010; Sela and Mills, 2010; 
Ward et al., 2006 and Zivkovic et al., 2010), only B. infantis ATCC 15697 and B. infantis M-
63 could ferment 3’-SL, 6’-SL, 2’-FL and 3’-FL (Table 3.5). In all cases, B. infantis M-63 
grew better than B. infantis ATCC 15697.  On the more complex LNnT, B. breve ATCC 
15700 and the two B. infantis strains grew well but not B. breve M-16V.  
No lactobacilli could significantly ferment 3’-SL, 6’-SL, 2’-FL and 3’-FL.  However, 
four lactobacilli were able to ferment LNnT including L. acidophilus NCFM, L. acidophilus 
La-5, L. plantarum LP-66 and L. reuteri (Table 3.6).  Based on the literature, it was not 
surprising to see minimal fermentation of 3’-SL, 6’-SL, 2’-FL and 3’-FL with lactobacilli.  
However, it is surprising to identify four lactobacilli that could ferment LNnT. 
3’-SL and 2’-FL Fermentation 
One interesting observation is that B. infantis can ferment 3’-SL and 2’-FL but could 
not ferment sialic acid or L-fucose.  Our hypothesis was that sialic acid and L-fucose 
accumulates in the media when B. infantis is grown on 3’-SL and 2’-FL, respectively.  If 
sialic acid accumulates in the growth media, then L. plantarum LP-66 should be able to 
ferment the newly available sialic acid.   
Compared with other bifidobacterial strains tested, B. infantis strains M-63 and 
ATCC 15697 had the highest growth on 3’-SL, with a ∆OD600 of 0.736 and 0.361, 
respectively. Confirming our bacterial growth kinetic analysis, HPLC analysis of B. infantis 
M-63 consumption showed that the concentration of 3’-SL only decreases (~70%) when B. 
infantis M-63 is present. However, no sialic acid accumulates in the growth media indicating 
that the B. infantis M-63 cells can utilize the sialic acid once it is inside the cell (Figure 3.1). 
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Similar to 3’-SL, B. infantis M-63 achieved excellent growth on 2’-FL with a ∆OD600 1.267 
and corresponding to a significant decrease in the 2’-FL concentration (~84%). However, L-
fucose does accumulate in the growth media when B. infantis M-63 ferments 2’-FL (Figure 
3.2).  
Unlike the other HMOs tested, a wider range of bacteria appeared to ferment LNnT in 
our growth kinetic analysis. In agreement with the growth data, the two B. infantis strains 
reduced the LNnT concentration the most B. infantis M-63 (91% consumption) and B. 
infantis ATCC15697 (89% consumption), respectively followed by B. breve ATCC15700 
(76% consumption) and then B. bifidum (23% consumption) (Figure 3.3).  
For lactobacilli, L. acidophilus NCFM consumed ~95% of the LNnT in the growth 
media. Interestingly, the product released from hydrolysis of LNnT appears to be lacto-N-
triose (LNTri), which is in agreement with HPLC analysis (see Chapter 4). LNTri did 
accumulate in the culture supernatant from L. acidophilus NCFM, representing hydrolysis of 
LNnT substrate. L. reuteri and L. rhamnosus exhibited more LNnT consumption. L. 
acidophilus NCFM and L. acidophilus La-5 had similar LNnT consumption but much less 
LNTri accumulated. 
 
3.5 DISCUSSION AND CONCLUSION  
This work suggested that there are significant differences amongst the tested strains 
regarding their ability to ferment HMO precursors and HMOs.  Of the 12 lactobacilli and 12 
bifidobacteria strains tested, only one Lactobacillus strain (L. plantarum LP-66) could 
ferment sialic acid and only two lactobacilli (L. rhamnosus GG ATCC 53103 and L. 
rhamnosus DR20) could ferment L-fucose.  No lactobacilli could ferment sialylated and 
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fucosylated HMOs: 3’-SL, 6’-SL, 2’-FL and 3’-FL yet four lactobacilli demonstrated 
moderate growth with LNnT.  In addition, the LNnT concentration significantly decreased 
when fermented by L. acidophilus NCFM.   
Amongst bifidobacteria, only B. longum subsp. infantis ATCC 15697 and B. longum 
subsp. infantis M-63 were able to ferment 3’-SL, 6’-SL, 2’-FL and 3’-FL.  When B. longum 
subsp. infantis M-63 was grown with 3’-SL, no change in sialic acid concentration was 
detected in the supernatant; however, when it was grown with 2’-FL, L‐fucose accumulated 
in the culture supernatant.  B. breve ATCC 15700, B. longum subsp. infantis ATCC 15697 
and B. longum subsp. infantis M-63 were able to ferment LNnT which was confirmed by 
HPLC analysis.   
Previous studies have demonstrated that human milk is a complex mixture of non-
digestible oligosaccharides that help maintain healthy gut microflora in infants. Only 
bifidobacteria and Bacteroides have been shown to be able to utilize HMOs (Marcobal et al. 
2010).  Recently B. bifidum, B. breve, B. infantis and B. longum were characterized for their 
capabilities for utilizing HMOs. Among the bifidobacteria strains, B. longum subsp. infantis 
and B. bifidum were shown to consume the HMOs most efficiently.  These common infant-
borne bifidobacteria possess different modes for consumption of HMOs. B. longum subsp. 
infantis likely imports the lower molecular weight oligosaccharides while B. bifidum exports 
fucosidases and lacto-N-biosidase for extracellular hydrolysis. In contrast, B. breve and B. 
longum subsp. longum grow on these oligosaccharides to lesser extent, while B. animalis and 
B. adolescentis are incapable of degrading HMOs (LoCascio et al. 2009). 
The analyses of growth and consumption of sialylated and fucosylated HMOs 
presented in this work have shown that only B. infantis was able to utilize these HMOs. Our 
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results are consistent with a previous study described by Sela et al. (2008) that reported that 
B. infantis ATCC 15697 isolated from infant feces possessed a gene cluster responsible for 
transport and utilization of non-digestible HMOs, which may explain why this 
Bifidobacterium predominates in the breast-fed infant GIT.  
Until recently, microbial interactions with milk sialyloligosaccharides (MSOs) have 
been solely characterized in terms of innate immune function. However, previous study by 
Almagro-Moreno and Boyd (2009) investigated the distribution, gene order, and molecular 
evolution of the cluster involved in sialic acid degradation (nanA, nanE, and nanK) among 
bacteria. They showed that the Nan cluster is present in some bacteria relevant to the gut.  In 
addition, N-acetylneuraminate lyase (NanA) is the key enzyme in sialic acid catabolism. 
NanA was present in four bacterial groups, -Proteobacteria, Planctomyces, 
Verrucomicrobia and Bacteroidetes. Sela et al (2011) reported that metabolism of sialylated 
HMOs can be an important factor for efficiency in HMO consumption. To utilize MSOs, B. 
longum subsp. infantis ATCC 15697 uses a sialidase that cleaves 2-6 and 2-3 linkages. 
NanH2, encoded within HMO catabolic cluster is active on sialylated lacto-N-tetraose 
(SLNT).   In this study, our HMO precursor results showed that only L. plantarum LP-66 
strain could ferment sialic acid. These data are consistent with the study by Almagro-Moreno 
and Boyd (2009) that L. plantarum is one of gut commensal microorganisms that have the 
Nan cluster.  Our subsequent study, 3’-SL fermentation by B. infantis M-63 showed no 
accumulation of sialic acid in the growth media suggesting that the B. infantis M-63 cells can 
utilize the sialic acid once it is inside the cell (Figure 3.4). This result is consistent with the 
proteomic analysis of B. longum subsp. infantis ATCC15697 suggesting that B. infantis 
strain possesses -sialidase. Interestingly, the expression of an -sialidase (Blon-2348) was 
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exclusive to the HMO proteome (Kim et al, 2012). Additionally, Zivkovic et al (2011) 
reported that B. infantis imports lower molecular-weight HMO via specific soluble binding 
proteins and transporters, followed by intracellular catabolism by a complement of 
glycosidases before entry of the monosaccharides into central metabolic pathways. 
Sela et al (2012) reported B. infantis ATCC 15697 fucosidases dedicated to 
fucosylated HMO metabolism. Previous research conducted on B. infantis ATCC 15697  
metabolism also reported that several small mass, fucosylated oligosaccharides are clearly 
preferred (LoCascio et al, 2007; LoCascio et al, 2009). Additionally, B. longum subsp. 
infantis VIII-240 was previously characterized as having a strong 1-2 fucolytic activity 
encoded by Blon_2335 (Larson et al, 1988). This gene was first identified as afcA in B. 
bifidum (Katayama T, et al. 2004; Nagae M, et al. 2007; Ashida H, et al. 2009). B. longum 
subsp. infantis, B. breve DSM20213 and B. pseudocatenulatum DSM20438 genomes include 
afcA homologs. Of the four afcA bifidobacteria, only B. bifidum secretes its afcA. In order to 
utilize fucosylated HMOs, B. infantis ATCC 15697 chromosome encodes five fucosidase 
genes. All five fucosidases are likely found in the cytosol, further distinguishing B. longum 
subsp. infantis from B. bifidum for the oligosaccharide transport. However, the analysis of 
ATCC 15697 genome did not reveal the genes of the fucose utilization pathway (Sela et al, 
2012). In this study, we demonstrated that the degradation of 2’-FL appeared to be associated 
with the accumulation of L-fucose in the culture supernatant by B. infantis M-63 (Figure 
3.2). The possibility that M-63 does not utilize L-fucose, but cleaves this HMO precursor 
from oligosaccharides, could be to access to a metabolizable portion of the molecule (Figure 
3.5). 
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Unfortunately, our fucosylated HMO results showed no lactobacilli could utilize 2’-
FL and 3’-FL. However, genome analysis of 25 Lactobacillus species revealed that only the 
L. casei-L. rhamnosus group encodes putative -L-fucosidases (Morita et al, 2009). In 
addition, Rodriguez-Diaz et al (2012) first reported of physiological characterization of an -
L-fucosidase in lactic acid bacteria and the utilization of Fuc--1,3-GlcNAc as a carbon 
source for bacteria. Three -L-fucosidase, AlfA, AlfB, and AlfC from L. casei BL23 were 
characterized. 
Previous studies by LoCascio et al (2007) have shown that B. breve ATCC15700 
consumed only a portion of a single nonfucosylated/nonsialylated HMO species, LNnT. 
Although LNnT is an abundant HMO in breast milk, the amount consumed by B. longum 
subsp. longum and B. breve represents only a small portion of the overall HMO pool. B. 
breve ATCC15700 was not able to consume the bulk of HMO structures, but did grow on all 
of the monomer constituents of HMO (Ward et al. 2007), suggesting a possible cross-feeding 
capacity in the GIT via liberated monosaccharides. In addition, Yoshida et al, 2012 showed 
that B. longum subsp. infantis uses two different β-galactosidases to selectively degrade the 
type-1 and type-2 HMOs. Miwa et al (2010) clarified that LNnT was sequentially degraded 
from its non-reducing terminus by extracellular exo-glycosidases and identified the genes 
encoding one extracellular β-galactosidase and two extracellular β-N-acetylhexosaminidases 
from B. bifidum JCM1254. The degradation of LNnT by B. bifidum JCM 1254 was shown to 
be the cooperative action of a β-galactosidase with an extracellular, membrane-bound β-N-
acetylhexosaminidase. This was sufficient to hydrolyze LNnT into galactose and lacto-N-
triose (LNTri) (Miwa et al, 2010).  LNnT was shown to be resistant to digestion by 
Bacteroides, Eubacterium, Clostridium and Enterococcus indicating that LNnT may be a 
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specific prebiotic for bifidobacteria (Miwa et al. 2010).  In this study, our LNnT results 
indicated that L. acidophilus NCFM could degrade LNnT and such degradation is 
accompanied by the liberation of LNTri (Chapter 5). A future challenge is to determine the 
mode of LNnT degradation by lactobacilli and genes that may have an important role in 
probiotic functionality. 
In summary, this present work we reported the in vitro growth behavior of different 
lactobacilli and bifidobacteria strains on sialylated and fucosylated HMOs, LNnT, and HMO 
precursors. HMOs are an abundant component of diets in breast-fed infants. The bacterial 
metabolism of HMO results indicated strain specific capabilities to differential metabolism of 
complex milk oligosaccharides. Differential growth of several bacteria species on the 
complex oligosaccharide substrate supports the principle that the prebiotic effect of human 
milk directs bacterial community and assigns milk’s microbiota.  
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3.6 TABLES AND FIGURES 
Table 3.1 Microorganisms used in this study 
Bacterial strain    Source 
Lactobacilli   
Lactobacillus Gasseri ATCC 33323 
Lactobacillus Acidophilus NCFM 
Lactobacillus Rhamnosus GG; ATCC 53103 
Lactobacillus Johnsonii ATCC 11506 
Lactobacillus Jensenii ATCC 25258 
Lactobacillus Johnsonii ACD-1/La-1 (Cargill) 
Lactobacillus Plantarum LP-66 (Cargill) 
Lactobacillus Paracasei LCV-1 (Cargill) 
Lactobacillus Acidophilus La-5 (Chr. Hansen) 
Lactobacillus Fermentum CECT 5716 
Lactobacillus Rhamnosus DR20 
Lactobacillus Reuteri Commercial isolate 
   
Bifidobacteria 
  
Bifidobacterium adolescentis ATCC 15703 
Bifidobacterium Infantis S12; ATCC 15697 
Bifidobacterium animalis subsp. lactis DSM 10140 
Bifidobacterium animalis subsp.animalis ATCC 25527 
Bifidobacterium Bifidum ATCC 29521 
Bifidobacterium Breve ATCC 15700 
Bifidobacterium Bifidum ATCC 11617 
Bifidobacterium Lactis Bf-6 (Cargill) 
Bifidobacterium Longum BB536 (Morinaga) 
Bifidobacterium Infantis M-63 (Morinaga) 
Bifidobacterium Breve M-16V (Morinaga) 
Bifidobacterium Lactis Bb-12 (Chr. Hansen) 
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Table 3.2 List of carbohydrates used in this study 
Carbohydrate Structure DP
 a
        Manufacturer or supplier 
D-Glucose α-D-Glc 1 Fisher Scientific 
D(+)-Galactose β-D-Gal 1 Acros-Organics 
Lactose Gal(β1-4)Glc 2 Fisher Scientific 
L-(-)Fucose 
 
1 Sigma-Aldrich 
D-Fructose 
 
1 Sigma-Aldrich 
Sialic acid  Neu5Ac 1 Calbiochem 
N-acetyl-D-glucosamine GlcNAc 1 Sigma-Aldrich 
3’-Sialyllactose Neu5Ac(α2-3)Gal(β1-4)Glc 3 V-labs; SL302 Lot# HGDX 76-161-1 
6’-Sialyllactose Neu5Ac(α2-6)Gal(β1-4)Glc 3 V-Labs; SL 306 Lot#HGDX21-163-1 
2’-Fucosyllactose Fuc(α1-2)Gal(β1-4)Glc 3 V-labs; Lot# DX103 
3’-Fucosyllactose Gal(β1-4)Fuc(α1-3)Glc 3 V-labs; Lot# DX807 
Lacto-N-neotetraose Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc 4 Abbott Nutrition 
a 
Degree of polymerization  
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Table 3.3 Utilization of human milk oligosaccharide precursors by bifidobacteria  
 
 
b 
GlcNAc, N-acetyl-D-glucosamine.
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Table 3.4 Utilization of human milk oligosaccharide precursors by lactobacilli  
 
 
b
GlcNAc, N-acetyl-D-glucosamine.  
c
Strain isolated from the commercial product.
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Table 3.5 Utilization of human milk oligosaccharides by bifidobacteria  
 
 
3'-SL,
 3’-Sialyllactose; 6'-SL, 6’-Sialyllactose; 2'-FL, 2’-Fucosyllactose; 3'-FL, 3’-Fucosyllactose; LNnT, Lacto-N-neotetraose.  
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Table 3.6 Utilization of human milk oligosaccharides by lactobacilli  
 
 
b 
Strain isolated from commercial product.
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 (A) 
 
(B) 
         
 
Figure 3.1 3’-Sialyllactose (3’-SL) consumption profiles. HPLC analysis of 3’-SL 
consumption by B. infantis M-63, L. plantarum LP-66 and their cocultures in sMRS+0.5 g/l 
L-cysteine supplemented with 10 g/l of 3’-Sialyllactose (3’-SL) at 37°C for 72 h in an 
anaerobic chamber. 3’-SL consumption is represented as the percent difference in 3’-SL 
between the start and the end of fermentation (A). Changes in 3’-SL (p<0.0001) and sialic 
acid (p=0.4953) concentrations after incubation are represented by concentration (g/l) Data 
with different letters are significantly different (B). Data represent average values from three 
independent experiments and error bars indicate standard deviations.   
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Figure 3.2 2’-Fucosyllactose (2’-FL) consumption profiles. HPLC analysis of 2’-FL 
consumption by B. infantis M-63 in sMRS+0.5 g/l L-cysteine supplemented with 10 g/l of 
2’-FL at 37°C for 48 h in an anaerobic chamber. 2’-FL consumption is represented as the 
percent difference in 2’-FL between the start and the end of fermentation (A). Changes in          
2’-FL and L-fucose concentrations after incubation are represented by concentration (g/l) 
(B). Data represent average values from three independent experiments and error bars 
indicate standard deviations.   
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Figure 3.3 Lacto-N-neotetraose (LNnT) consumption profiles. HPLC analysis of LNnT 
consumption by bifidobacteria and lactobacilli in sMRS or sMRSC supplemented with 10 g/l 
of LNnT at 37°C for 96 h in an anaerobic chamber. LNnT consumption is represented as the 
percent difference in LNnT (p<0.0001) between the start and the end of fermentation (A). 
Changes in LNTri (p<0.0001) released from LNnT hydrolysis after incubation are 
represented by concentration (g/l) (B). Data represent average values from three independent 
experiments and error bars indicate standard deviations.   
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Figure 3.4 The potential metabolic pathway for 3’-Sialyllactose (3’-SL) consumption in B. 
infantis M-63 
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Figure 3.5 The potential metabolic pathway for 2’-Fucosyllactose (2’-FL) consumption in B. 
infantis M-63. 
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CHAPTER 4  
METABOLISM OF HUMAN MILK OLIGOSACCHARIDE, 
LACTO-N-NEOTETRAOSE BY SELECTED LACTOBACILLI AND 
BIFIDOBACTERIA STRAINS 
 
4.1 ABSTRACT 
Human milk is unique because of the high concentration and diversity of human milk 
oligosaccharides (HMOs). Although HMOs are documented prebiotic compounds, the 
utilization of individual components of HMOs by lactobacilli is not well characterized.  Our 
previous study demonstrated the ability of lactobacilli and bifidobacteria to digest individual 
major HMO components (Chapter 3). Amongst bifidobacteria, only B. infantis ATCC 15697 
and B. infantis M-63 were able to ferment 3’-Sialyllactose (3'-SL), 6’-Sialyllactose (6'-SL), 
2’-Fucosyllactose (2'-FL), and 3’-Fucosyllactose (3'-FL). No lactobacilli could ferment the 
HMOs 3’-SL, 6’-SL, 2’-FL and 3’-FL. Interestingly, we observed a unique activity of a more 
complex HMO, Lacto-N-neotetraose (LNnT).
 
LNnT, in providing a growth factor for B. 
infantis, B. breve, L. acidophilus, L. plantarum and L. reuteri.  In this study, high 
performance liquid chromatography and thin layer chromatography results confirmed that 
amongst the tested strains, L. acidophilus NCFM was found to be the most efficient 
lactobacillus utilizing LNnT. In addition, we characterized the consumption of LNnT by L. 
acidophilus NCFM and further investigated a -galactosidase gene involved in LNnT 
utilization by L. acidophilus NCFM. β-galactosidase lacL gene knockout in L. acidophilus 
NCFM and subsequent carbohydrate utilization analysis demonstrated that LNnT was unable 
to be utilized by the knockout strain, confirming that β-galactosidase lacL gene is required 
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for LNnT utilization. Additionally, growth curves of the lacL knockout strain showed a 
reduced growth rate on lactose and galactose, and an extended lag phase on lactose 
suggesting that the β-galactosidase lacL gene plays a significant role in LNnT, lactose and 
galactose utilization in L. acidophilus NCFM.
 
 
4.2 INTRODUCTION 
Human Milk Oligosaccharides (HMOs) are structurally classified into 13 core 
structures with all possessing a lactose unit at the reducing end (Amano et al, 2009; Kobata, 
2010; Urashima et al, 2012). HMOs can be further categorized based on the linkage of the 
disaccharide unit at the non-reducing end into type 1 (1-3 linkage) and type 2 (1-4 linkage) 
structure.  Type 1 HMOs are more abundant and include lacto-N-tetraose (LNT), lacto-N-
fucopentaose I (LNFP I), or lacto-N-difucohexaose I (LNDFH I) (Thurl et al, 2010; 
Urashima et al., 2012).  Of the type 2 HMOs, lacto-N-neotetraose (LNnT) [Gal(β1-
4)GlcNAc(β1-3)Gal(β1-4)Glc] is the most abundant and is typically present at 0.17-0.45 g/l 
in mature human milk (Chaturvedi et al., 2001; Newburg et al., 2004; Asakuma et al., 2008; 
Thurl et al., 2010). However, data on the fermentation of LNnT by relevant gut microbes is 
limited. 
Probiotics are defined as live microorganisms which when administered in sufficient 
amounts will have beneficial effects on the host health (FAO/WHO, 2002).  Recent 
comparative studies demonstrated that probiotics and their health benefits are strain specific 
(Douillard et al., 2013). The diverse health benefits of probiotic bacteria may be due to 
various mechanisms of action and strain-specific properties of probiotics (Nagpal et al., 
2012). The health beneficial effects of probiotic bacteria include i) improvement of GIT 
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health by regulation of microbiota, ii) stimulation and development of the immune system, 
iii) reduction of symptoms of lactose intolerance, and iv) reduction of risk of certain cancers 
(Parvez et al, 2006).   
Lactobacillus species are lactic acid bacteria (LAB), widely used as probiotics and 
are abundant in the mammalian gut.  LAB is a group of phylogenetically related 
microorganisms that make lactic acid as a primary metabolic end product. L. acidophilus 
NCFM is one of the most common L. acidophilus probiotics used commercially and has the 
ability to survive in the GIT (Sanders and Klaenhammer, 2001; Sui et al, 2002), adhere to 
human epithelial cells in vitro (Greene and Klaenhammer, 1994; Sanders and Klaenhammer, 
2001), modify fecal flora (Sui et al, 2002), and modulate the host immune response and 
prevent microbial gastroenteritis (Varcoe et al, 2003).  
The L. acidophilus NCFM genome sequence revealed several genes potentially 
involved in the uptake and metabolism of a diversity of carbohydrates (Altermann et al, 
2005). It has been shown that a variety of L. acidophilus strains are able to utilize several 
polysaccharides and oligosaccharides (Kaplan et al, 2000; Van Laere et al, 2000). 
Additionally, L. acidophilus NCFM has the ability to use nondigestible oligosaccharides such 
as FOS and GOS (Barrangou et al, 2003). A large number of predicted glycoside hydrolases 
differentiate lactobacilli and bifidobacteria from most other bacteria that are typically found 
throughout the mammalian GIT  (Altermann et al, 2005; Gänzle and Follador, 2012). 
Several studies have determined the ability of bifidobacteria to assimilate type 1 and 
type 2 HMOs (Wada et al, 2008; Miwa et al, 2010; Yoshida et al, 2012). However, the 
degradation pathway of LNnT (type 2 structure) in lactobacilli has not yet been successfully 
identified.  In this study, our objective was to investigate the metabolism of LNnT by 
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selected lactobacilli and bifidobacteria. In order to understand the utilization of LNnT, a time 
course of LNnT degradation in L. acidophilus was characterized using high performance 
liquid chromatography (HPLC) and thin layer chromatography (TLC). Additionally, a -
galactosidase gene (lacL) involved in LNnT utilization by L. acidophilus NCFM was 
identified. In the present study, our results expand the current knowledge of HMOs 
metabolism in lactobacilli. 
 
4.3 MATERIALS AND METHODS 
Bacterial Cultures 
Growth of Lactobacilli and Bifidobacteria in Media Containing LNnT 
Bacterial culture procedures have been previously described in Chapter 3. All 
bacterial strains used for growth assays are listed in Table 4.1.   Carbohydrates used for this 
study were listed in Table 4.2 
Kinetic Analysis of Bacterial Growth 
Kinetic analysis of bacterial growth procedure was previously described in Chapter 
Characterization of Degradation of LNnT in Selected Lactobacilli and Bifidobacteria 
by HPLC and TLC 
High Performance Liquid Chromatography (HPLC) 
For the analysis of LNnT utilization, the post-fermentation supernatants (250 l) were 
taken at the indicated times over the course of 96 h and centrifuged at 12,000 x g for 10 min, 
and the resulting supernatants were immediately stored at -20°C until further analysis. 
Changes in LNnT and LNTri concentrations after fermentation were determined by HPLC, 
(Agilent Technologies 1200 Series) equipped with a refractive index detector using a Rezex 
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ROA-Organic Acid H
+
 (8%) column (Phenomenex Inc.). The column was eluted with 0.005 
N of H2SO4 at a flow rate of 0.6 ml/min at 50°C (Ha et al., 2011).   
Thin Layer Chromatography (TLC) 
Lactobacilli were cultured on sMRS supplemented with 1% LNnT at 37C for 96 h in 
an anaerobic chamber. The post fermentation supernatants from 24, 48, 72, and 96 h were 
analyzed. N-acetylglucosamine (GlcNAc), glucose (Glc), galactose (Gal), lactose (Lac), 
Lacto-N-triose (LNTri) and Lacto-N-neotetraose (LNnT) were used as standards. Hydrolysis 
of LNnT was assessed by TLC using the method described by Miwa et al. (2010). A mixture 
of 1-butanol:acetic acid:water in a 2:1:1 ratio was used as a solvent. Plates were sprayed with 
diphenylamine:aniline:phosphoric acid in ethanol, and developed at 120C for 5 min.  
β-galactosidase Activity of Culture Supernatants 
Standard assay for β-galactosidase activity was performed using the methods of 
Ghose & Bisaria (1987) and Garrido et al. (2013). Enzymatic assays were carried out with a 
reaction mixture containing 80 µl of McIlvaine buffer, 15 µl of 0.05M o-nitrophenyl-β-D-
galactopyranoside (ONPG; Sigma-Aldrich, St. Louis, MO) and 5 µl of post-fermentation 
supernatants at 37°C for 10 min.  The reaction was then stopped by adding 1 M Na2CO3. The 
release of o-nitrophenol was quantified by measuring absorbance at 405 nm using the 
Thermo LabSystems Multiskan Ascent (Thermo LabSystems, Beverly, MA). One unit of 
activity was defined as the amount of enzyme liberating 1µmol of o-nitrophenol per min. 
DNA Isolation, Manipulations and Transformations 
Genomic DNA of L. acidophilus NCFM was isolated using the Microbial DNA 
isolation kit (MO BIO, Carlsbad, CA) according to the manufacturer’s instruction.  Plasmid 
DNA from E. coli was carried out using the QIAprep Spin Miniprep kit (QIAGEN, Valencia, 
60 
 
CA). DNA manipulations were performed using standard procedures (Sambrook and Russell, 
2001). Single stranded oligonucleotide primers used in this study were designed using Clone 
Manager 9 and synthesized by IDT (Integrated DNA Technologies, Coralville, IA). For 
cloning, restriction enzyme sites were added at 5’ end of the primers. PCR reactions were 
carried out using EconoTaq polymerase (Lucigen, Middleton, WI). PCR fragments were 
purified using the Qiagen PCR purification kit (QIAGEN, Valencia, CA). Restriction 
enzymes and T4 DNA ligase were obtained from New England Biolabs. Chloramphenicol (5 
μg/mL for Lactobacillus) and erythromycin (150 μg/mL for E. coli and 5 μg/mL for 
Lactobacillus) were used when necessary for selection. Electrocompetent L. acidophilus 
NCFM cells were prepared using 3.5X Sucrose MgCl2 electroporation buffer (3.5X SMEB) 
as described by Luchansky et al., (1991). The electroporation was performed using the 
Electroporator 2510 (Eppendorf, Westbury, NY) at a setting of 2.5kV, 25μFD, 200Ω.  
Inactivation of L. acidophilus NCFM -galactosidase (lacL) Gene  
In this study, -galactosidase gene (lacL, LBA1467) was chosen to be inactivated 
based on the likelihood to be involved in complex oligosaccharide hydrolysis in L. 
acidophilus NCFM (Andersen et al, 2011).  The inactivation of lacL was carried out by 
targeted insertion of an erythromycin resistant (Em
r
), non-replicative vector pMJM43 by 
homologous recombination using previously established method (Russell and Klaenhammer, 
2001).   
To create pMJM43, the primers lacLF_BamHI and lacLR_XbaI (Table 4.5) were 
used to amplify a 945 bp internal region of lacL from L. acidophilus NCFM. This fragment 
was cloned via the BamHI/XbaI sites into pORI28, an Ori
+
, RepA
-
 integration plasmid. 
Plasmid pMJM43 (placL) was then introduced into L. acidophilus NCFM carrying pTRK669 
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(MJM8) by electroporation. RepA function was provided by the temperature-sensitive helper 
plasmid pTRK669, which is stable at 37C but not at 42C. Creation of the lacL knockout 
followed a procedure previously described (Russell and Klaenhammer, 2001) The single 
cross-over event was verified by PCR amplification of the junction fragments from 
chromosomal DNA of Em
r
 colonies. The 5’ junction fragment demonstrating integration in 
the lacL gene (primers ori+: 5’-ATAATGAACTGTGCTGATTAC-3’ and   lacL-: 5’- 
GGATCGTAGACTAAGAGCGC-3’) had an expected size of 1385 bp.  The 3’ junction 
fragment demonstrating integration in the lacL gene (primers ori-: 5’-
TTCAATCGCCAACGAATC-3’ and lacL+: 5’-CACAATCCCAGTTCCTAGTG -3’) had 
an expected size 1315 bp.  Only the strains containing pMJM43 inserted in the desired 
orientation produced the expected PCR products. 
Carbohydrate Utilization Analysis 
The lacL knockout strain was analyzed for the ability to utilize Glc, Gal, Lac, and 
LNnT as compared to the parental strain. The growth assay was performed using semi-
synthetic MRS with erythromycin (5 µg/ml) supplemented with 1% (wt/vol) carbohydrate on 
Bioscreen C as previously described in bacterial cultures (Chapter 3). 
 
4.4 RESULTS 
Bacterial Growth Assay of LNnT Consumption by Bifidobacteria and Lactobacilli  
The bacterial growth assay of LNnT was previously described in Chapter 3. 
Lactobacilli could not ferment sialylated and fucosylated HMOs (3’-SL, 6’-SL, 2’-FL and 3’-
FL) (Table 4.3) and few of them showed some growth on the nonsialylated and 
nonfucosylated HMO, LNnT (Table 4.4 and Figure 4.1).  
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Determination of LNnT Degradation  
In order to further characterize LNnT fermentation, we used an HPLC approach to 
analyze bacterial consumption of LNnT. Post-fermentation supernatants from four 
bifidobacteria strains, B. infantis M-63, B. infantis ATCC 15697, B. breve ATCC 15700 and 
B. bifidum ATCC 11617 were taken at 96 h and analyzed by HPLC. In agreement with the 
previous growth data, the two B. infantis strains were found to be the most efficient 
bifidobacteria strains in terms of the LNnT consumption (Figure 4.2A).  LNnT concentration 
was reduced by 88% with B. infantis M-63 and 86% with B. infantis ATCC15697.  
For lactobacilli, four strains were tested: L. acidophilus NCFM, L. acidophilus La-5, 
L. reuteri, and L. rhamnosus ATCC 53103. L. acidophilus NCFM was found to be the most 
efficient Lactobacillus to consume LNnT. L. acidophilus NCFM consumed 93% of the LNnT 
in the growth media as shown in Figure 4.2A while L. reuteri and L. rhamnosus exhibited 
more LNnT consumption. L. acidophilus NCFM and L. acidophilus La-5 had similar LNnT 
consumption but much less LNTri accumulated (Figure 4.2B). 
A time course of LNnT consumption by L. acidophilus NCFM and L. acidophilus La-
5 was performed. After 24 h incubation, the amount of LNnT was decreased and a LNTri 
appeared concurrently with L. acidophilus NCFM. No other LNnT degradation products 
were significantly detected.  During 48-96 h, the concentration of LNnT decreased and 
LNTri increased (Figure 4.3). Similar results were obtained using HPLC as well (Figure 
4.5).  Lacto-N-biose (LNB) was not detected at any time point (Figure 4.4). L. acidophilus 
La-5 showed a much slower consumption of LNnT compared to L. acidophilus NCFM which 
correlated to their respective growth kinetics (Figure 4.3 and 4.4). These results suggested 
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that LNnT was sequentially utilized outside of the cells of L. acidophilus NCFM by an 
extracellular glycosidase such as β-galactosidase.  
Analysis of LNnT Fermentation and β-galactosidase Activity                         
Post-fermentation supernatants were taken at indicated times (0, 24, 48, 72, and 96 h). 
Figure 4.6 shows growth curves and β-galactosidase activities of L acidophilus NCFM 
(Figure 4.6A) and L. acidophilus La-5 (Figure 4.6B). L. acidophilus NCFM reached the 
highest cell density at 48h during growth in the presence of LNnT and exhibited higher β-
galactosidase activity in culture supernatants than L. acidophilus La-5. This result correlated 
with HPLC and TLC data (Figure 4.3 and 4.4) where we demonstrated LNTri released from 
hydrolysis of LNnT. For L. acidophilus La-5, an extended lag phase with low β-galactosidase 
activity was observed.  
Inactivation of -galactosidase Gene (lacL) 
  In order to confirm that -galactosidase is required for LNnT utilization, a lacL 
(LBA1467) knockout strain in L. acidophilus NCFM was evaluated for growth on glucose, 
galactose, lactose and LNnT. Upon analysis, the growth assay revealed that the L. 
acidophilus NCFM wild-type could utilize lactose and LNnT (Figure 4.7A), while the lacL 
knockout strain could not utilize LNnT and showed a delayed and reduced growth on lactose 
(Figure 4.7B). Confirming the carbohydrate utilization analysis, HPLC analysis of utilization 
of LNnT by L. acidophilus NCFM and lacL knockout strain showed that the concentration of 
LNnT only decreased  when  L. acidophilus NCFM wild-type is present  (Figure 4.8). These 
results confirmed that -galactosidase gene (lacL) is required for the utilization of LNnT by 
L. acidophilus NCFM. 
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4.5 DISCUSSION AND CONCLUSION 
HMOs are composed of both neutral and anionic species with building blocks of five 
monosaccharides: D-glucose, D-galactose, N-acetylglucosamine (GlcNAc), L-fucose, and N-
acetylneuraminic acid (Zivkovic et al., 2011).  HMOs are considered as prebiotics since they 
stimulate growth of certain beneficial bacteria, e.g. bifidobacteria (Coppa et al, 2006; 
Chichlowski et al., 2011; Yu et al., 2013).   Schwab and Ganzle (2011) determined that LAB 
isolated from the feces of neonates were not able to utilize complex HMOs. To date limited 
information exists on HMO metabolism or fermentation of HMOs by LAB.  Recent L. 
acidophilus NCFM genome sequence revealed that 17% of the genes present in the genome 
are responsible for carbohydrate uptake and catabolism (Altermann et al., 2005).  Broad 
carbohydrate utilization of L. acidophilus NCFM was demonstrated and included transporters 
for trehalose (Doung et al., 2006), FOS (Barrangou et al., 2003), and several other mono-, di-
and trisaccharides.  
Previous work by Andersen et al (2011) identified the lac gene cluster by 
transcriptional and functional analysis in L. acidophilus NCFM. Subsequently, the identified 
lacS (lactose permease) was evaluated by lacS knockout and phenotypic confirmation. The 
lac gene cluster includes two -galactosidase-encoding genes (lacLM, LBA1467-LBA1468 
and lacA, LBA1462). These β-galactosidase genes are assigned to the glycoside hydrolase 
family 2 (GH2) and glycoside hydrolase family 42 (GH42), respectively using CAZy 
classification (Cantarel et al, 2009). In addition, genomic comparison of B. infantis 
ATCC15697, B. longum DJO10A, Bacteroides fragilis ATCC25285, and Bacteroides 
vulgatus ATCC8482 revealed that GH2 and GH42 -galactosidases have been shown to be 
involved in the metabolism of pooled HMOs (Marcobal et al., 2010).  
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It has been previously reported that LNnT was sequentially digested from non-
reducing end by extracellular exo-glycosidases in bifidobacteria. Genes encoding 
extracellular β-galactosidase (EC 3.2.1.23) and two extracellular β-N-acetylhexosaminidase 
(EC 3.2.1.52) were identified  from B. bifidum JCM1254 (Miwa et al, 2010). In contrast to 
the metabolic pathway specific for LNnT in bifidobacteria, the pathway has not yet been 
investigated in lactobacilli. In fact, we were unable to find any publications that have 
identified β-N-acetylhexosaminidase activity in lactobacilli.  Our bioinformatic analysis has 
identified candidates for this gene in the sequenced genomes of a few lactobacilli genomes.  
Thus, studying the occurrence of enzyme releasing LNTriose in lactobacilli is important, not 
only for a better understanding of the LNnT/LNTriose pathway, but also for elucidating the 
degradation pathway of HMOs with a type 2 structure. In this study, we demonstrated that 
the utilization of tetrasaccharide LNnT in L. acidophilus NCFM is accompanied by the 
liberation of LNTri consistent with the activity of a -galactosidase. Considering L. 
acidophilus β-galactosidase enzymatic activities during growth on LNnT, the results of this 
study further suggested that β-galactosidase appeared to be involved in the release of LNTri 
from LNnT hydrolysis.   
In this study, we confirmed the role of β-galactosidase in LNnT degradation by 
inactivation of L. acidophilus NCFM lacL gene. Creation of lacL gene knockout in L. 
acidophilus NCFM and subsequent carbohydrate utilization analysis demonstrated that LNnT 
was unable to be utilized by the knockout strain, confirmimg that β-galactosidase lacL gene 
is required for LNnT utilization. In addition, growth curves of the lacL knockout strain 
showed a reduced and delayed growth on lactose suggesting that the β-galactosidase lacL 
gene plays a significant role in lactose and LNnT utilization in L. acidophilus NCFM. 
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In conclusion, our results have shown the importance of characterization of β-
galactosidase lacL function. Based on the lacL knockout results, lacL is responsible for the 
utilization of LNnT and lactose. The preference of L. acidophilus for LNnT may contribute 
to their documented abundance of lactobacilli in breast-fed and formula-fed infant feces and 
intestinal microbiota (Satokari et al., 2002; Salminen and Guiemonde, 2005; 
Charalampopoulos and Rastall, 2009).  
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4.6 TABLES AND FIGURES 
 
Table 4.1 Microorganisms used in this study 
 
Bacterial strain    Source 
Lactobacilli   
Lactobacillus gasseri ATCC 33323 
Lactobacillus acidophilus NCFM 
Lactobacillus rhamnosus GG; ATCC 53103 
Lactobacillus johnsonii ATCC 11506 
Lactobacillus jensenii ATCC 25258 
Lactobacillus johnsonii ACD-1/La-1 (Cargill) 
Lactobacillus plantarum LP-66 (Cargill) 
Lactobacillus paracasei LCV-1 (Cargill) 
Lactobacillus acidophilus La-5 (Chr. Hansen) 
Lactobacillus fermentum CECT 5716 
Lactobacillus rhamnosus DR20 
Lactobacillus reuteri Commercial isolate 
   
Bifidobacteria 
  
Bifidobacterium adolescentis ATCC 15703 
Bifidobacterium infantis S12; ATCC 15697 
Bifidobacterium animalis subsp. lactis DSM 10140 
Bifidobacterium animalis subsp.animalis ATCC 25527 
Bifidobacterium bifidum ATCC 29521 
Bifidobacterium breve ATCC 15700 
Bifidobacterium bifidum ATCC 11617 
Bifidobacterium lactis Bf-6 (Cargill) 
Bifidobacterium longum BB536 (Morinaga) 
Bifidobacterium infantis M-63 (Morinaga) 
Bifidobacterium breve M-16V (Morinaga) 
Bifidobacterium lactis Bb-12 (Chr. Hansen) 
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Table 4.2 Carbohydrates used for this study 
 
Carbohydrate Source 
Dextrose (D-Glucose) Fisher Scientific 
D(+)-Galactose ACROS-ORGANICS 
-Lactose Fisher Scientific 
L-(+)-Lactic acid Sigma-Aldrich 
GlcNAc (N-acetyl-D-glucosamine) Sigma-Aldrich 
LNnT (Lacto-N-neotetraose) Abbott Nutrition 
LNTri (Lacto-N-triose) Carbosynth 
LNB (Lacto-N-biose) Carbosynth 
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Table 4.3 Fermentation of human mIlk oligosaccharides and human mIlk oligosaccharide 
precursors by bifidobacteria 
 
 
 
 
3'-SL,
 3’-Sialyllactose; 6'-SL, 6’-Sialyllactose; 2'-FL, 2’-Fucosyllactose; 3'-FL, 3’-
Fucosyllactose; LNnT, Lacto-N-neotetraose.
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Table 4.4  Fermentation of human mIlk oligosaccharides and human mIlk oligosaccharide 
precursors by lactobacilli 
 
 
 
 
3'-SL,
 3’-Sialyllactose; 6'-SL, 6’-Sialyllactose; 2'-FL, 2’-Fucosyllactose; 3'-FL, 3’-
Fucosyllactose; LNnT, Lacto-N-neotetraose.
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Table 4.5 Bacterial strains and plasmids used for -galactosidase gene (lacL) knockout   
 
Strain or plasmid Relevant characteristics Source or reference 
Strains 
   L. acidophilus     
       NCFM human intestinal isolate Barefoot and Klaenhammer, 1983 
       MJM350 L. acidophilus NCFM  lacL::pMJM43 This study 
 
   E. coli     
       EC1000 RepA
+
 MC1000, Km
 r
,
 
carrying a single copy of the pWV01 repA gene 
in the glgB gene; host for pORI28-based plasmids 
Russell and Klaenhammer, 2001 
       NCK1609 EC1000 (pORI28) Russell and Klaenhammer, 2001 
 
Plasmids     
      pORI28 
      pTRK669 
Em
 r
,
  
ori (pWV01), replicates only with repA provided in trans 
ori (pWV01), Cm
 r
, provides repA in trans, temperature sensitive 
Russell and Klaenhammer, 2001 
Russell and Klaenhammer, 2001 
      pMJM43 (placL) 2.6 kb, pORI28 with 945 bp internal L. acidophilus NCFM lacL 
fragment 
This study 
72 
 
Table 4.6 Primer sequences of -galactosidase gene (lacL) knockout   
 
Gene Primers Sequences (5'3') 
lacL lacLF_BamHI
a
  ATGCGGATCCTGCCGAACGAGCCATGTATG 
 lacLR_XbaI
 b
 AATTTCTAGACCGGCATAAGATTCGTTTCC 
5’ junction fragment   Ori
+
         ATAATGAACTGTGCTGATTAC 
     lacL
_     
     GGATCGTAGACTAAGAGCGC 
3’ junction fragment   Ori 
_
         TTCAATCGCCAACGAATC 
     lacL
+          CACAATCCCAGTTCCTAGTG 
 
a
lacLF_BamHI, the forward primer containing the BamHI site (underlined). 
b
lacLR_Xba, the reverse primer containing the XbaI site (underlined).
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Figure 4.1 Microtitre plate-based growth curves of bifidobacteria and lactobacilli. Growth 
curves of bifidobacteria (A) and lactobacilli (B) in sMRS supplemented with 1% (w/v) 
LNnT. Growth was measured as optical density (OD) of the media at 600 nm (absorbance 
reading 30 min intervals, 30 sec shaking every 30 min at max. speed). Controls consisted of 
inoculated medium lacking carbohydrate (H2O). All strains were grown in three independent 
assays. Curves are the average of the three assays. 
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(B) 
 
 
 
 
 
 
 
 
Figure 4.2 Lacto-N-neotetraose (LNnT) consumption profiles. HPLC analysis of LNnT 
consumption by bifidobacteria and lactobacilli in sMRS or sMRSC supplemented with 10 g/l 
of LNnT at 37°C for 96 h in an anaerobic chamber. LNnT consumption is represented as the 
percent difference in LNnT (p<0.0001) between the start and the end of fermentation (A). 
Changes in LNTri (p<0.0001) released from LNnT hydrolysis after incubation are 
represented by concentration (g/l) (B). Data represent average values from three independent 
experiments and error bars indicate standard deviations.   
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Figure 4.3 Time course analysis of LNnT fermentation by L. acidophilus NCFM (lane 2-6) 
and L. acidophilus La-5 (lane 7-11). Lane1: mixture of standard Lacto-N-neotetraose 
(LNnT), Lacto-N-triose (LNTri), Lactose (Lac), Galactose (Gal), Glucose (Glc), and N-
acetyl-D-glucosamine (GlcNAc); Lane 2-6: L. acidophilus NCFM; Lane 7-11: L. acidophilus 
La-5; Lane 12: sMRS+1%LNnT; Lane 13: mixture of standard LNnT, LNTri, Lac, Gal, Glc, 
and GlcNAc; Lane 14: LNnT; Lane 15: LNTri, Lane 16: Lac; Lane 17: Gal; Lane 18: Glc; 
Lane 19: GlcNAc. 
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(A) 
 
(B) 
 
 
 
Figure 4.4  Time course analysis of post-fermentation supernatants of L. acidophius NCFM 
(A) and L. acidophilus La-5 (B) cultured on a semi-synthetic MRS (sMRS) medium 
supplemented with 1% (w/v) Lacto-N-neotetraose (LNnT). Results are the average of three 
independent experiments, and error bars indicate standard deviations. LNTri, Lacto-N-triose; 
Lacto-N-biose, LNB; N-acetyl-D-glucosamine, GlcNAc. 
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Figure 4.5 HPLC chromatograms of post-fermentation supernatants of L. acidophilus NCFM 
cultured in sMRS+1% (w/v) LNnT at 0, 24, 48, 72, and 96 h. LNnT, Lacto-N-neotetraose; 
LNTri, Lacto-N-triose.  
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Figure 4.6  Growth profiles and β-galactosidase activity of L. acidophilus NCFM (A) and L. 
acidophilus La-5 (B) on sMRS supplemented with 1% (wt/vol) Lacto-N-neotetraose (LNnT). 
Results are the average of three independent experiment.
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Figure 4.7 Growth profile of L. acidophilus NCFM wild-type (A) and lacL gene knockout 
strain (B) grown on semi-synthetic MRS (sMRS) plus glucose (glc), lactose (lac) and Lacto-
N-neotetraose (LNnT). Results are the average of three independent experiments.  
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Figure 4.8 Changes in LNnT concentration during incubation of L. acidophilus NCFM wild-
type (WT) and lacL knockout strain (NCFM lacL) in semi-synthetic MRS (sMRS) 
supplemented with 10 g/l of Lacto-N-neotetraose (LNnT) at 37°C for 120 h in an anaerobic 
chamber. Data represent average values from three independent experiments and error bars 
indicate standard deviations.  
 
 
 
 
 
 
 
 
 
Treatment 
%
C
o
n
su
m
p
ti
o
n
 
81 
 
CHAPTER 5 
PREBIOTIC GALACTOOLIGOSACCHARIDE METABOLISM BY PROBIOTIC 
LACTOBACILLI AND BIFIDOBACTERIA 
 
5.1 ABSTRACT 
The consumption of prebiotic galactooligosaccharide (GOS) by lactobacilli was 
investigated by comparison with selected bifidobacteria in order to determine the metabolism 
of GOS, utilization patterns and potential of probiotic and prebiotic combinations. Analysis 
of matrix-assisted laser desorption/ionization time-of-flight and thin layer chromatography of 
cell-free supernatants taken during growth of five probiotic bacteria suggested differences in 
the utilization of GOS. Lactobacillus rhamnosus DR20 and B. lactis Bb-12 preferentially 
utilized disaccharides, while L. fermentum and B. infantis utilized mostly di- and 
trisaccharides over larger DP GOS. Among the tested strains, only L. acidophilus NCFM 
showed extracellular and intracellular β-galactosidase activity. Interestingly, L. acidophilus 
NCFM showed a preference to consume Purimune GOS (GOS-P) with DP 2 and 3 and larger 
DP GOS (DP 4-6) and released galactose very efficiently from GOS-P. L. acidophilus 
NCFM lacL gene knockout and subsequent carbohydrate utilization analysis demonstrated 
that GOS-P was unable to be utilized by the knockout strain, confirming that β-galactosidase 
lacL gene is required for GOS-P utilization. Our results suggesting that the lacL gene 
involved in GOS-P consumption by L. acidophilus NCFM and revealed the role of functional 
lacL -galactosidase is important for the metabolism of lactose and complex carbohydrates 
for the survival of intestinal lactobacilli in GI tract.   
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5.2 INTRODUCTION 
Probiotics are live microorganisms which when administered in adequate amounts 
confer beneficial effects on the host health (FAO/WHO, 2002). Potential benefits of 
probiotics have been described including inhibition of pathogenic microorganisms, 
stimulation of host immune response, prevention of colon cancer, lowering of cholesterol 
levels and improvement of lactose digestion (Coconnier et al., 1993; Vinderola et al., 2006; 
Uccello et al., 2012; Kumar et al., 2012; Savaiano, 2014). 
Lactobacilli are dominant microorganisms in fermented food products and applied as 
probiotic cultures to exert health benefits on the host. L. acidophilus is one of the main 
species of lactic acid bacteria that has been used as probiotics (Itsaranuwat et al., 2003) and 
displays the ability to catabolize a diverse number of oligosaccharides and prebiotic 
compounds (Andersen et al., 2012). Despite the recent interest in galactooligosaccharide 
(GOS) utilization, the information about metabolism and enzymes involved in the utilization 
of GOS by Lactobacillus species remain to be investigated.  L. acidophilus NCFM is to date 
one of few strains of this species for which the genome has been sequenced, annotated and 
published (Altermann et al., 2005; Oh et al., 2011; Stahl and Barrangou, 2013).  In addition, 
several genetic determinants important in probiotic functionality have been identified in L. 
acidophilus NCFM (Guarner et al., 2008).   
The term “prebiotic” is defined as nondigestible food ingredients that confer a 
beneficial effect on the host by selectively stimulating the growth and/or activity of bacteria 
in the colon (Gibson and Roberfroid, 1995). Due to the definition of prebiotics, there are 
three following criteria used to characterize a prebiotic compound: i) resistance to hydrolysis 
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by human enzymes; ii) fermentation by intestinal microbiota; and iii) selective stimulation of 
the growth and/or metabolic activity of beneficial bacteria in GIT (Roberfroid, 2007).  The 
most common commercially available prebiotics include inulin, FOS, and GOS.  
GOS are complex carbohydrates and normally composed of a lactose core and 
galactose polymer with a terminal galactose or glucose attached in either -(12, 3, 4 or 6). 
Commercial GOS production can have a degree of polymerization (DP) of 2 up to 6 (Torres 
et al, 2010; Gänzle, 2012; Gänzle and Follador, 2012). GOS are applied as food ingredients 
and are widely used in food products in North American and European markets due to the 
fact that they are similar to components of human milk and can be produced cheaply from 
lactose via a transglycosylation reaction by the use of enzyme -galactosidase (Torres et al, 
2010). There have been several studies that have included GOS in infant formula and this 
supplementation has been reported to promote the growth of beneficial bacteria such as 
bifidobacteria and lactobacilli (Moro et al, 2002; Macfarlane et al, 2008; Nakamura et al, 
2009; Davis et al, 2010). 
Studies on production of prebiotic GOS and GOS metabolism by bifidobacteria have 
been well studied so far (Hsu et al, 2007; Depeint et al, 2008; Barboza et al, 2009; Garrido et 
al, 2013; Andersen et al, 2013). However, mechanisms and higher oligosaccharide degrading 
enzymes involved in prebiotic catabolism by lactobacilli remain to be characterized.  The aim 
of this study was to investigate the metabolism of prebiotic GOS by selected lactobacilli and 
bifidobacteria.  In this study we reported the use of matrix-assisted laser 
desorption/Ionization time-of-flight mass spectrometry (MALDI-TOF MS) and thin layer 
chromatography (TLC) approaches to determine the prebiotic GOS consumption profile and 
demonstrated that an extracellular -galactosidase is essential for a degradation of prebiotic 
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GOS components with a higher degree of polymerization (DP>3) by L. acidophilus NCFM. 
In general, the results of this study can thus significantly improve our understanding of GOS 
metabolism by lactobacilli and bifidobacteria.  
 
5.3 MATERIALS AND METHODS  
Purification of GOS 
Purified GOS was obtained by purification of Purimune™ GOS (GOS-P) (90-92% 
total GOS, DP 2-6; GTC Nutrition; Appendix B) and Vivinal
® 
GOS (GOS-V) (Dry matter 
75% of which 59% GOS, Friesland Foods Domo; Appendix B).  Stock solutions of 1.5 g/100 
ml were applied to a XK column (XK 50/100 column, 5.0x100cm, GE healthcare) packed 
with Sephadex G25 medium (Sigma-Aldrich, St. Louis, MO).  The column was eluted with 
pure distilled water at a rate of 8 ml/min and was collected in 12 ml fractions by a Gilson FC 
203B fraction collector.  
Detection of carbohydrate was performed using the phenol–sulfuric acid assay 
(Masuko et al, 2005).  Briefly, 50 μl of sample (2 l of fraction and 48 μl of distilled water) 
was added to 150 l of concentrated sulfuric acid rapidly in a 96-well microtitre plate. 
Immediately thereafter, 30 l of 5% phenol was added and the plate was kept in a static 
water bath at 80C for 30 min.  After cooling to room temperature, the absorbance at 490 nm 
was measured by a SpectraMax Plus384 Spectrophotometer (Molecular Devices, Sunnyvale, 
CA).  Based on carbohydrate analysis, fractions containing minimal di- and monosaccharides 
85 
 
(fractions 30-55) were pooled and freeze dried (Freeze dry system, Freezezone 4.5, 
LABCONCO, Kansas City, MO) for bacterial fermentation experiments.   
Organisms and Growth Conditions 
Bacterial culture procedures have been previously described in Chapter 3. All 
bacterial strains used for growth assays in this study are listed in Table 5.1.   Carbohydrates 
used for this study were listed in Table 5.2 
Kinetic Analysis of Bacterial Growth 
 Kinetic analysis of bacterial growth procedure was previously described in Chapter 3. 
Utilization of GOS-P and β-Galactosidase Activity   
β-galactosidase activity was determined as described by Miller (1972). Cells were 
harvested from 1 ml of liquid culture by centrifugation (10,000 x g, 10 min at room 
temperature), washed twice with 50 mM sodium phosphate buffer (pH 7) and resuspended in 
1 ml of Z  buffer (60 mM Na2HPO4

7H2O, 40 mM NaH2PO4

H2O, 10 mM KCl, 1 mM 
MgSO4

7H2O and 50 mM -mercaptoethanol). The OD600 was measured and cells were 
disrupted by shaking for 5 min with 10 µl of 0.1% SDS and 40 µl of chloroform. -
galactosidase was assayed in the permeabilized cell and the spent medium using o-
nitrophenyl-β-D-galactopyranoside (ONPG; Sigma-Aldrich, St. Louis, MO) as the 
chromogenic substrate. The reaction started by adding 200 µl of 10 mM ONPG to 100 µl of 
permeabilized cells and the volume was made up to 1 ml with 50 mM sodium phosphate 
buffer (pH 7). After 15 min at 37C, the reaction was stopped by adding 1 ml of 1 M Na2CO3 
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and the OD420 and OD550 were analyzed on a spectrophotometer (SpectraMax M2e, 
Molecular Devices, Sunnyvale, CA). -galactosidase activity was expressed in Miller Units.  
Units = 1,000 x OD420 - (1.75 x OD550)    
          t x V x OD600  
OD600= optical density of cells just before assay, OD550 = optical density of cells debris after 
assay, A420 = absorbance of o-nitrophenol released, t= reaction time (min), V= volume of 
culture used (ml). The units are proportional to the increase in o-nitrophenol per minute per 
bacterium (Miller, 1972).  
Characterization of Post-Fermentation of GOS-P 
Analysis of GOS-P Utilization by Matrix-Assisted Laser Desorption/Ionization 
Time-of-Flight Mass Spectrometry (MALDI-TOF MS) 
The oligosaccharide profiles of post-fermentation cell free supernatants were 
determined using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF). 
An aliquot of supernatant was dried in vaccuo and labeled with 2-aminobenzamide (2-AB) as 
follows.  To the dried samples, 10 µl of 2-AB labeling reagent (0.35 M 2-AB, 1 M 
NaCNBH3 in 70:30 (vol/vol) DMSO:Glacial Acetic Acid) was added and the reaction mix 
was incubated at 65C for 2.5 h.  Following incubation the 2-AB labeled samples were 
cooled to room temperature and centrifuged.  Excess 2-AB reagent was removed from the 
labeled samples with the use of a Glycoclean S-Cartridge (Prozyme, Hayward, CA) 
following the manufacturers recommended procedure.  Once eluted from the S-cartridge, the 
purified labeled samples were dried in vaccuo.   
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The 2-AB tagged sample was dissolved in 100 µl of MilliQ water and 1 µl of that was 
mixed with 1 µl of 0.1%TFA aqueous solution. This reaction mixture was then mixed with 2 
µl of Super-DHB (mixture of 0.5M DHB and 0.1M 5-Methoxy Salicylic acid in MeOH) 
matrix (1:1 v/v) and spotted on MALDI plate. MALDI mass spectra were acquired at 
positive more using 4800 Plus MALDI-TOF/TOF instrument (AB Sciex) equipped with 337 
nm solid state laser. The data was processed with Data Explorer software and area of the 
corresponding m/z was obtained from the peak list.  
Thin layer chromatography (TLC) 
Hydrolysis of GOS-P was assessed using the method described by Garrido et al. 
(2013) with some modifications. In this study glucose, galactose and lactose were used as 
standards. Following incubation at 37C for 24 h, post-fermentation supernatants (2 µl) were 
spotted onto TLC Silica gel plates (Sigma-Aldrich, St. Louis, MO). The TLC plates were 
developed in a mixture of n-propanol, acetic acid and water in a 2:1:1 ratio. Plates were 
sprayed with 0.5% -naphthol and 5% H2SO4 in ethanol, and visualized by heating at 120C 
for 10 min. 
DNA Isolation, Manipulations and Transformations 
The procedure of DNA isolation, manipulation  and transformation  was previously 
described in Chapter 4.  
Inactivation of L. acidophilus NCFM -galactosidase (lacL) Gene  
The procedure of inactivation of L. acidophilus NCFM -galactosidase (lacL) gene 
was previously described in Chapter 4.  
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Carbohydrate Utilization Analysis  
The lacL knockout strain was analyzed for the ability to utilize on glucose, galactose, 
lactose and GOS-P compared to the L. acidophilus NCFM wild-type. The growth assay was 
performed in a Bioscreen C 100-well honeycomb plate using semi-synthetic MRS with 
erythromycin (5 µg/ml) supplemented with 1% (wt/vol) carbohydrate as described previously 
in organisms and growth conditions. 
 
5.4 RESULTS 
Purification of GOS 
GOS is produced by the transgalactosylation of lactose and is a mixture of many 
different carbohydrates which may include mono- and disaccharides.  In order to test the 
fermentation parameters of GOS and not the mono- and disaccharides which would not 
normally reach the colon, we used column chromatography to purify a GOS fraction 
essentially free of mono- and disaccharides. We used glucose (monosaccharide), lactose 
(disaccharide) and raffinose (trisaccharide) as standards.  Consistent with information from 
the suppliers, GOS-P has less mono- and disaccharides than GOS-V. For example, the GOS-
P peaked before the raffinose peak suggesting that Purimune GOS consists primarily of 
trisaccharides or larger.  For GOS-V, the peak was observed at a similar fraction number as 
lactose.  Since lactose begins to appear in fraction 55, we used fractions 30 through 55 for 
our purified GOS from both suppliers (Figure 5.1).  
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Fermentation of Prebiotic Galactooligosaccharides 
The majority of the bifidobacteria strains tested could ferment GOS from both 
suppliers (Table 5.3).  In general, the growth of the bifidobacteria was greater with GOS-V 
than GOS-P.  Removal of mono- and disaccharides from GOS resulted in a decrease in 
growth for most bifidobacteria.  Both B. infantis strains were among the best growers on 
purified GOS as determined by OD confirming that GOS is a reasonable prebiotic to add to 
infant formula if the goal is to increase B. infantis.  All bifidobacteria tested except for B. 
animalis ATCC 25527 were able to utilize scFOS whereas no bifidobacteria were able to 
utilize polydextrose (PDX).    
Similar to bifidobacteria, the lactobacilli strains tested grew better on GOS-V than 
GOS-P due to the higher amounts of mono- and disaccharides found in GOS-V (Table 5.4).  
Removal of these mono- and disaccharides resulted in a less growth.  All of the lactobacilli 
were able to utilize scFOS except for L. rhamnosus GG, L. paracasei LCV-1, L. fermentum 
CECT 5716, L. rhamnosus DR20 and L. reuteri.  No lactobacilli were able to utilize PDX 
except for minimal growth seen with L. plantarum LP-66 and L. reuteri (Table 5.4).   
Growth of Probiotic Bacteria on Prebiotic GOS-P and the Presence of β-galactosidase 
Activity 
β-Galactosidase is a key enzyme  necessary for GOS fermentation (Andersen et al. 
2011).  We hypothesized that larger GOS polymers will not be fermentable by probiotics 
with β-galactosidase present solely inside the cell since the GOS transporter (Ganzle and 
Follador, 2012) will not be able to import the larger polymers.  Conversely, strains that 
secrete β-galactosidase will hydrolyze the GOS polymers into smaller units outside the cell 
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which can then be imported inside the cell.   In this study, we assessed β-galactosidase 
activity of cell-free culture supernatants (extracellular β-galactosidase) and permeabilized 
cells (intracellular β-galactosidase). 
Figure 5.2 shows growth curves of lactobacilli and bifidobacteria in the presence of 
GOS-P as the carbon source. L. acidophilus NCFM, L. fermentum CECT5716, L. rhamnosus 
DR20 and B. infantis M-63 grew well, while B. lactis Bb-12 had a longer lag phase and 
reached stationary phase at 24h. -galactosidase activity in L. acidophilus NCFM differs 
from other probiotic bacteria tested in this study. Among the tested strains, only L. 
acidophilus NCFM showed extracellular and intracellular β-galactosidase activity.  The 
highest extracellular β-galactosidase activity (575 U) was found in L. acidophilus NCFM 
(Figure 5.2) at mid-log phase (12 h) and then decreased. While other lactobacilli and 
bifidobacteria did not exhibit considerable extracellular β-galactosidase activity. In contrast, 
the highest intracellular β-galactosidase activity (3077 U) was found in L. fermentum 
CECT5716 during stationary phase.  
Utilization of GOS-P Determined by MALDI-TOF MS and TLC Analysis  
To understand the utilization of GOS-P by probiotic bacteria, the cell-free culture 
supernatants were collected at 24 h, purified, and analyzed using MALDI-TOF compared 
with the uninoculated controls. MALDI-TOF was able to detect signals at m/z 485.08, 
647.12, 809.14, 971.16, and 1133.22 corresponding to oligosaccharides with degrees of 
polymerization (DP) ranging from 2 to 6, respectively. The intensities of MALDI-TOF mass 
spectra for the cell-free culture supernatants from probiotic bacteria cultures on a semi-
synthetic MRS medium supplemented with 1% GOS are shown in Figure 5.3.   
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In general, all 5 strains tested were able to consume the smaller oligosaccharides to a 
great extent. L. fermentum CECT5716 and B. infantis M-63 (Figure 5.3C and 5.3F) 
preferentially utilized di- and trisaccharides (DP=2 and 3) over larger DP GOS (DP > 4).  L. 
rhamnosus DR20 and B. lactis Bb-12 (Figure 5.3D and 5.3G) preferentially utilized 
disaccharides (DP=2) over larger DP GOS (DP> 3). Interestingly, L. acidophilus NCFM 
showed a preference to consume all GOS (Figure 5.3B) and released galactose very 
efficiently from GOS-P. Similar results were obtained by TLC (Figure 5.4).     
Investigation of -galactosidase Gene Involved in GOS-P Consumption by L. 
acidophilus NCFM   
 In order to investigate that -galactosidase lacL is required for GOS-P utilization for 
L. acidophilus NCFM, the lacL knockout strain was evaluated for the ability to grow on 
glucose, galactose, lactose and GOS. Upon analysis, the growth assay showed that the L. 
acidophilus NCFM wild-type could utilize lactose and GOS-P, while the lacL knockout 
mutant showed a longer lag phase and reduced growth rate on lactose and no growth on 
GOS-P (Figure 5.5). These results confirmed that -galactosidase lacL gene is required for 
the utilization of lactose and GOS-P by L. acidophilus NCFM.  
 
5.5 DISCUSSION AND CONCLUSION  
Since the long term goal of prebiotic approach and dietary supplementation includes 
i) impact on the gut microbiota; ii) improve gut function; iii) prevent systemic disease and  
iv) increase population of natural bifidobacteria and lactobacilli in the intestinal microbiota 
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through the use of prebiotics. Many of prebiotic investigations have been reported to increase 
numbers of bifidobacteria and have focused on changes in bifidobacteria abundance as a 
measure of prebiotic effects. (Garrido et al, 2013; Lecerf et al, 2012; Ramirez-Farias et al, 
2009; Macfarlane et al, 2008; Roberfroid et al, 1998). However, those studies may represent 
overestimates of the actual prebiotic consumption.  Here we demonstrated that bifidobacteria 
and lactobacilli strains tested grew better on GOS-V than GOS-P due to the greater amounts 
of mono- and disaccharides. Additionally, we confirmed that the removal of mono- and 
disaccharides from GOS-P and GOS-V has resulted in a less growth by bifidobacteria and  
lactobacilli.  However, B. infantis strains tested in this study were among the best growers on 
purified GOS. These results support that it is reasonable to use dietary supplementation with 
GOS, to modulate the B. infantis population.   
Previous studies indicated that bifidobacteria have been shown to utilize complex 
oligosaccharides such as GOS (Barboza et al., 2009), FOS (Bouhnik et al., 2006) and inulin 
(Ramirez-Farias et al., 2009).  Garrido et al. (2013) suggested that mechanisms involved in 
utilization of these prebiotics by bifidobacteria include oligosaccharide transporters and -
galactosidase. To date, few transport systems specific for GOS, FOS and maltodextrin have 
been identified in L. plantarum and L. acidophilus (Barrangou et al, 2003; Saulnier et al, 
2007; Nakai et al, 2009). Andersen et al (2011) previously identified the genes in L. 
acidophilus NCFM responsible for the transport and catabolism of GOS. Within the lac gene 
cluster, lacS, a galactoside-pentose-hexuronide permease-encoding gene, was up-regulated  
in the presence of GOS. In addition, the presence of lacS and lacA homologs among the 
intestinal lactobacilli supports the importance of complex galactoside utilization. Overall, 
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these studies demonstrated that L. acidophilus NCFM lacS is important for survival in the 
GIT via transport and metabolism of lactose, GOS, and likely fractions of HMOs.  
The human gut contains a complex microbial community which is dominated by 
bacterial phylotypes belonging to Firmicutes, Bacteroidetes and Actinobacteria. Gill et al 
(2006) reported that human gut metagenomes encode for a huge diversity of enzymes 
involved in carbohydrate transport and metabolism. Since the human genome does not 
encode adequate carbohydrate active enzyme, the intestinal microbiota plays a key role in 
host nutrition by harvesting energy from dietary carbohydrates and fibers which are not 
digested in the upper part of the digestive tract (Flint et al, 2008).  In this study, we analyzed 
the GOS fraction utilized by different probiotic bifidobacteria and lactobacilli to evaluate our 
hypothesis that extracellular β-galactosidase is necessary to ferment the larger GOS polymers 
present in GOS-P. Accordingly, our results suggested that extracellular -galactosidase 
enzyme is essential for degradation of galactooligosaccharide with a degree of 
polymerization >3 in L. acidophilus NCFM.  
In this study, the role of β-galactosidase in GOS-P utilization was further confirmed 
by inactivation of L. acidophilus NCFM lacL gene. Creation of lacL gene knockout in L. 
acidophilus NCFM and subsequent carbohydrate utilization analysis demonstrated that GOS-
P was unable to be utilized by the knockout strain, confirmimg that β-galactosidase lacL gene 
is required for GOS-P utilization. In addition, growth curves of the lacL knockout strain 
showed a reduced growth on lactose and galactose, and a delayed growth on lactose 
suggesting that lacL gene plays a significant role in lactose and galactose utilization in L. 
acidophilus NCFM. In conclusion, our results suggesting that the -galactosidase lacL gene 
involved in GOS-P consumption by L. acidophilus NCFM and revealed the role of functional 
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lacL -galactosidase is important for the metabolism of lactose and complex carbohydrates 
for the survival of intestinal lactobacilli in GI tract.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
5.6 TABLES AND FIGURES  
Table 5.1 Bacterial strains used in this study 
Bacterial strain    Source 
Lactobacilli   
Lactobacillus gasseri ATCC 33323 
Lactobacillus acidophilus NCFM 
Lactobacillus rhamnosus GG; ATCC 53103 
Lactobacillus johnsonii ATCC 11506 
Lactobacillus jensenii ATCC 25258 
Lactobacillus johnsonii ACD-1/La-1 (Cargill) 
Lactobacillus plantarum LP-66 (Cargill) 
Lactobacillus paracasei LCV-1 (Cargill) 
Lactobacillus acidophilus La-5 (Chr. Hansen) 
Lactobacillus fermentum CECT 5716 
Lactobacillus rhamnosus DR20 
Lactobacillus reuteri Commercial isolate 
   
Bifidobacteria 
  
Bifidobacterium adolescentis ATCC 15703 
Bifidobacterium infantis S12; ATCC 15697 
Bifidobacterium animalis subsp. lactis DSM 10140 
Bifidobacterium animalis subsp.animalis ATCC 25527 
Bifidobacterium bifidum ATCC 29521 
Bifidobacterium breve ATCC 15700 
Bifidobacterium bifidum ATCC 11617 
Bifidobacterium lactis Bf-6 (Cargill) 
Bifidobacterium longum BB536 (Morinaga) 
Bifidobacterium infantis M-63 (Morinaga) 
Bifidobacterium breve M-16V (Morinaga) 
Bifidobacterium lactis Bb-12 (Chr. Hansen) 
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Table 5.2 Carbohydrates used for this study 
Carbohydrate Source 
Dextrose (D-Glucose) Fisher Scientific 
D(+)-Galactose ACROS-ORGANICS 
-Lactose Fisher Scientific 
GOS-P (Purimune™Galactooligosaccharide) GTC Nutrition 
Purified GOS-P (Purimune™Galactooligosaccharide) This study 
GOS-V (Vivinal
®
Galactooligosaccharide) Friesland Foods  
Purified GOS-V (Vivinal
®
Galactooligosaccharide) This study 
scFOS (Short-Chain Fructooligosaccharide) Nutraflora®P-95 (GTC Nutrition) 
PDX (Litesse
®
Polydextrose) DANISCO 
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Table 5.3 Growth of bifidobacteria on prebiotics  
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Table 5.4 Growth of lactobacilli on prebiotics 
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Table 5.5 Bacterial strains and plasmids 
Strain or plasmid Relevant characteristics Source or reference 
Strains 
   L. acidophilus     
       NCFM human intestinal isolate Barefoot and Klaenhammer 1983 
       MJM350 L. acidophilus NCFM  lacL::pMJM43 This study 
 
   E. coli     
       EC1000 RepA
+
 MC1000, Km
 r
,
 
carrying a single copy of the pWV01 repA gene 
in the glgB gene; host for pORI28-based plasmids 
Russell and Klaenhammer 2001 
       NCK1609 EC1000 (pORI28) Russell and Klaenhammer 2001 
 
Plasmids     
      pORI28 
      pTRK669 
Em
 r
,
  
ori (pWV01), replicates only with repA provided in trans 
ori (pWV01), Cm
 r
, provides repA in trans, temperature sensitive 
Russell and Klaenhammer 2001 
Russell and Klaenhammer 2001 
      pMJM43 (placL) 2.6 kb, pORI28 with 945 bp internal L. acidophilus NCFM lacL 
fragment 
This study 
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Table 5.6 Primer sequences of -galactosidase gene (lacL) knockout   
 
Gene Primers Sequences (5'3') 
lacL lacLF_BamHI  ATGCGGATCCTGCCGAACGAGCCATGTATG 
 lacLR_XbaI  AATTTCTAGACCGGCATAAGATTCGTTTCC 
5’ junction fragment   Ori
+
         ATAATGAACTGTGCTGATTAC 
     lacL
_     
     GGATCGTAGACTAAGAGCGC 
3’ junction fragment   Ori 
_
         TTCAATCGCCAACGAATC 
     lacL
+          CACAATCCCAGTTCCTAGTG 
a
lacLF_BamHI, the forward primer containing the BamHI site (underlined). 
b
lacLR_Xba, the reverse primer containing the XbaI site (underlined).
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Figure 5.1 Chromatograms showing the separation of (A) Purimune™GOS (GOS-P) and (B) 
Vivinal®GOS (GOS-V) using analytical Sephadex®G-25 column (XK 50/100 column, 5x100 
cm, GE healthcare) at the flow rate 8 ml/min. Fractions 30-55 were pooled and freeze dried for 
bacterial fermentation experiments. Glucose, lactose and raffinose were run on the column to 
identify the fractions for mono-, di- and trisaccharides respectively. 
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Figure 5.2 Growth of bifidobacteria and lactobacilli on GOS-P and -galactosidase activity in 
cell-free supernatant and permeabilized cells;  L. acidophilus NCFM (A); L. fermentum 
CECT5716 (B); L. rhamnosus DR20 (C); B. infantis M-63 (D); and B. lactis Bb-12 (E).                    
(    ), OD600; (   ), -galactosidase activity/ OD600 in permeabilized cells; (    ), -galactosidase 
activity/ OD600 in cell-free supernatant. 
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Figure 5.3  MALDI-TOF mass spectrometry analysis of sMRS supplemented with 1% GOS-P 
(A) and postbiotic supernatants obtained from bacteria cultures with 1%GOS-P by L. acidophilus 
NCFM (B); L. fermentum CECT5716 (C); L. rhamnosus DR20 (D); sMRSC supplemented with 
1% GOS-P (E); B. infantis M-63 (F); and B. lactis Bb-12 (G). 
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Figure 5.4 Thin layer chromatography (TLC) analysis of postbiotic supernatants from 24h-
fermentation of 1% GOS-P. Lane1: 1%glucose; lane2: 1%galactose; lane3: 1%lactose; lane4: 
MJM7 L. acidophilus NCFM; lane5: MJM108 L. fermentum CECT5716; lane6: MJM109 L. 
rhamnosus DR20; lane7: MJM93 B. infantis M-63 (Morinaga); lane8: MJM95 B. lactis Bb-12 
(Chr. Hansen); lane9: sMRS+1%GOS; lane10: sMRS+0.5g/l L-Cysteine+1%GOS-P. 
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 (B) 
 
Time (h) 
Figure 5.5 Growth curves of L. acidophilus NCFM wild type (A) and lacL gene knockout strain 
(B) grown on semi-synthetic MRS (sMRS) plus glucose (glc), lactose (lac) and GOS-P. 
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CHAPTER 6  
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
Human milk oligosaccharides (HMOs) are believed to have a range of biological 
activities beyond providing nutrition to the infant. Principal among these is that they may act as 
prebiotics. Prebiotics are dietary ingredients, usually oligosaccharides that provide a health 
benefit to the host mediated by the modulation of the human gut microbiota. While it is clear that 
such oligosaccharides may have potential applications in infants, this potential is limited by the 
difficulties in manufacturing HMO. Consequently, functional alternatives such as 
galactooligosaccharides (GOS) are under investigation. GOS are produced enzymatically from 
lactose for commercial use in food applications including addition to infant formula as similar to 
breast milk oligosaccharides, they encourage a gut bacteria population that promotes health and 
reduces the incidence of intestinal infections. Our studies focused on understanding the effects of 
individual major sialylated and fucosylated HMO components, nonsialylated/nonfucosylated 
LNnT and prebiotic GOS on the in vitro growth behavior of different lactobacilli and 
bifidobacteria strains. In a subsequent study, we investigated the metabolism of LNnT and 
prebiotic GOS utilization patterns and confirmed a gene involved in consumption of these 
complex oligosaccharides. 
In the first study, our objective was to identify probiotics that can ferment HMOs and 
determine the growth characteristics of probiotics cultured on HMOs and HMO precursors. 
Overall, the results showed that amongst the bifidobacteria strains tested, only   B. infantis strains 
were able to ferment 3'-Sialyllactose (3’-SL), 6'-Sialyllactose (6’-SL), 2’-Fucosyllactose (2’-FL) 
and 3’-Fucosyllactose (3’-FL). None of the bifidobacteria and very few lactobacilli could utilize 
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either free L-fucose or sialic acid. Only B. infantis, B. breve, L. acidophilus, L. plantarum and L. 
reuteri were able to ferment LNnT, which was confirmed by HPLC analysis.  Despite the lack of 
the whole genome sequence of B. infantis M-63, no conclusions on the L-fucose and sialic acid 
utilization pathway. Our results demonstrated that there are differences in metabolisms of milk 
oligosaccharides among lactobacilli and bifidobacteria strains.  It would also be interesting to 
further study the use of probiotics for their benefits and possible side effects, if any. However, it 
is important that the probiotic strains for human use should undergo animal studies followed by 
human clinical trials in order to authenticate the suitability, safety, and benefits of probiotics for 
human consumption and development of functional foods. 
 According to the first study, our second study further investigated the consumption of 
LNnT by selected lactobacilli and bifidobacteria. Overall, the results showed a unique activity of 
LNnT in providing a growth factor for B. infantis, B. breve, L. acidophilus, L. plantarum and L. 
reuteri.  Interestingly, L. acidophilus NCFM was found to be the most efficient Lactobacillus 
strain to utilize LNnT. The results of  L. acidophilus β-galactosidase enzymatic activities during 
growth on LNnT sugggesting β-galactosidase appeared to be involved in the release of LNTri 
from LNnT hydrolysis.  Further analysis of -galactosidase activity and identification of -
galactosidase gene suggesting that β-galactosidase lacL gene involved in LNnT utilization by L. 
acidophilus NCFM.  β-galactosidase lacL gene knockout in L. acidophilus NCFM and 
subsequent carbohydrate utilization analysis demonstrated that LNnT was unable to be utilized 
by the knockout strain, confirmimg that β-galactosidase lacL gene is required for LNnT 
utilization. Our results suggested that the preference of L. acidophilus for LNnT may contribute 
to their documented abundance of lactobacilli in breast-fed and formula-fed infant feces and 
intestinal microbiota. 
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In the third study, our objective was to investigate the consumption of prebiotic GOS by 
selected lactobacilli and bifidobacteria in order to determine the metabolism of GOS and GOS 
utilization patterns. Overall results showed that five probiotic bacteria showed differences in the 
utilization of GOS. L. rhamnosus DR20 and B. lactis Bb-12 preferentially utilized disaccharides, 
while L. fermentum and B. infantis utilized mostly di- and trisaccharides over larger DP GOS. 
Only L. acidophilus NCFM showed extracellular and intracellular β-galactosidase activity. 
Interestingly, L. acidophilus NCFM showed a preference to consume GOS with DP 2 and 3 and 
larger DP GOS (DP 4-6). Our results suggesting that the -galactosidase lacL gene involved in 
GOS consumption by L. acidophilus NCFM and revealed the role of functional lacL -
galactosidase is important for the metabolism of lactose and complex carbohydrates for the 
survival of intestinal lactobacilli in GI tract. Despite the lack of molar detector, no quantitative 
conclusions on the rate of degradation of GOS and the consumption of mono-and dimers. Further 
studies, involving quantitative detection of metabolites generated are required in order to 
elucidate the exact mechanisms involved in the uptake and metabolism of GOS by lactobacilli. 
In conclusion, as the knowledge about intestinal microbiota, nutrition, immunity, and 
genetics in infant health and disease has increased in the past years, such information and our 
observations could certainly help to develop new probiotic strains with specific functions and 
could also facilitate the understanding of potential use of probiotics. Further investigations on the 
effects of probiotics and prebiotics on gut health should assess the complete microbial ecosystem 
and not just selected bacterial groups. Monitoring total population shift will improve our 
understanding of mode of action of prebiotics and the key role of prebiotic to promote the host 
health and provide the information for infant nutrition study in the future. 
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APPENDIX A 
KINETIC ANALYSIS OF HMO PRECURSORS, HMOS, AND 
PREBIOTICS FERMENTATION BY BIFIDOBACTERIA AND LACTOBACILLI 
  Table A.1 Kinetic analysis of HMO precursor fermentation by bifidobacteria 
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APPENDIX A (continued) 
Table A.2   Kinetic analysis of HMO precursor fermentation by lactobacilli 
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APPENDIX A (continued) 
 Table A.3   Kinetic analysis of GOS fermentation by bifidobacteria  
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APPENDIX A (continued) 
Table A.4 Kinetic analysis of GOS fermentation by lactobacilli  
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    APPENDIX A (continued) 
Table A.5    Kinetic analysis of HMO fermentation by bifidobacteria 
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APPENDIX A (continued) 
Table A.6 Kinetic analysis of HMO fermentation by lactobacilli 
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APPENDIX B 
OLIGOSACCHARIDE CONFIGURATION AND DISTRIBUTION OF 
GALACTOOLIGOSACCHARIDES 
Table B.1 Oligosaccharide configuration and distribution of Purimune™ GOS (GOS-P) 
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   APPENDIX B (continued) 
Table B.2   Oligosaccharide configuration and distribution of Vivinal
® 
GOS (GOS-V) 
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APPENDIX B (continued) 
 
 
 
Figure B.1 -(1,4) linked galactooligosaccharide molecule of Purimune™ GOS (GOS-P) 
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APPENDIX C 
SUPPLEMENTAL INFORMATION FOR HMO CONSUMPTION  
Table C.1   GLM procedure and analysis of 3’-SL consumption. 
 
3SL 
 
The MEANS Procedure 
treat=1 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 2.3100000 1.0328601 0.5963221 1.5700000 3.4900000 
 
treat =2 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 2.9900000 0.8665449 0.5002999 2.4600000 3.9900000 
 
treat =3 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 9.4800000 0.6385139 0.3686462 8.7900000 10.0500000 
 
treat =4 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 9.3900000 0.7238094 0.4178915 8.7400000 10.1700000 
 
treat =5 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.3500000 0.1769181 0.1021437 0.1600000 0.5100000 
 
 
 
 
The GLM Procedure 
Class Level Information 
Class Levels Values 
Treat 5 1 2 3 4 5 
 
Number of Observations Read 15 
Number of Observations Used 15 
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APPENDIX C (continued) 
Table C.1 (continued) GLM procedure and analysis of 3’-SL consumption. 
 
3SL 
 
The GLM Procedure 
Dependent Variable: bacteria  
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 4 216.5853600 54.1463400 97.36 <.0001 
Error 10 5.5612000 0.5561200   
Corrected Total 14 222.1465600    
 
R-Square Coeff Var Root MSE bacteria Mean 
0.974966 15.20666 0.745735 4.904000 
 
Source DF Type III SS Mean Square F Value Pr > F 
Treat 4 216.5853600 54.1463400 97.36 <.0001 
 
 
 
Treatment  
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APPENDIX C (continued) 
Table C.2  GLM procedure and analysis of changes in sialic acid  concentrations after 
incubation  
 
Sialic acids 
 
The MEANS Procedure 
treat=1 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.5033333 0.4365012 0.2520141 0.0300000 0.8900000 
 
treat =2 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.9666667 0.4200397 0.2425100 0.5500000 1.3900000 
 
treat =3 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.4533333 0.3800439 0.2194184 0.0700000 0.8300000 
 
treat =4 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.7600000 0.5196152 0.3000000 0.4600000 1.3600000 
 
treat =5 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.8266667 0.0642910 0.0371184 0.7800000 0.9000000 
 
The GLM Procedure 
Class Level Information 
Class Levels Values 
treat 5 1 2 3 4 5 
 
Number of Observations Read 15 
Number of Observations Used 15 
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APPENDIX C (continued) 
Table C.2 (continued) GLM procedure and analysis of changes in sialic acid concentrations 
after incubation   
 
Sialic acids 
 
The GLM Procedure 
Dependent Variable: bacteria  
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 4 0.57077333 0.14269333 0.91 0.4953 
Error 10 1.57106667 0.15710667   
Corrected Total 14 2.14184000    
 
R-Square Coeff Var Root MSE bacteria Mean 
0.266487 56.46251 0.396367 0.702000 
 
Source DF Type III SS Mean Square F Value Pr > F 
treat 4 0.57077333 0.14269333 0.91 0.4953 
 
 
 
Treatment 
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APPENDIX C (continued) 
Table C.3 GLM procedure and analysis of LNnT consumption 
 
LNnT 
 
The MEANS Procedure 
treat=1 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 87.7420000 0.8308705 0.4797033 87.1598000 88.6935000 
 
treat =2 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 87.1254667 4.5317983 2.6164350 81.9063000 90.0628000 
 
treat =3 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
2 71.7960000 11.7717723 8.3239000 63.4721000 80.1199000 
 
treat =4 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 13.9506333 1.7422535 1.0058906 12.2630000 15.7428000 
 
treat =5 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
2 84.5195500 1.2249211 0.8661500 83.6534000 85.3857000 
 
treat =6 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
2 69.3045500 6.0488035 4.2771500 65.0274000 73.5817000 
 
treat =7 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 12.8401333 7.3049624 4.2175220 5.7013000 20.3006000 
 
treat =8 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 1.1100667 3.4838938 2.0114270 -1.8693000 4.9407000 
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APPENDIX C (continued) 
Table C.3 (continued) GLM procedure and analysis of LNnT consumption 
 
LNnT 
 
The GLM Procedure 
Dependent Variable: bacteria  
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 7 27694.51352 3956.35907 144.40 <.0001 
Error 13 356.18904 27.39916   
Corrected Total 20 28050.70256    
 
R-Square Coeff Var Root MSE bacteria Mean 
0.987302 10.37453 5.234420 50.45453 
 
Source DF Type III SS Mean Square F Value Pr > F 
nutri 7 27694.51352 3956.35907 144.40 <.0001 
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APPENDIX C (continued) 
Table C.4 GLM procedure and analysis of changes in LNTri concentrations after incubation   
 
LNTri 
 
The MEANS Procedure 
treat=1 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.8785667 0.3739157 0.2158803 0.4469000 1.1022000 
 
treat =2 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.8967667 0.1685741 0.0973263 0.7936000 1.0913000 
 
treat =3 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.3634000 0.2178123 0.1257540 0.1387000 0.5736000 
 
treat =4 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.7227000 0.2611010 0.1507467 0.5655000 1.0241000 
 
treat =5 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 2.3543333 0.0422500 0.0243931 2.3121000 2.3966000 
 
treat =6 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.1822667 0.0526980 0.0304252 0.1506000 0.2431000 
 
treat =7 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
2 0.4195000 0.0219203 0.0155000 0.4040000 0.4350000 
 
treat =8 
Analysis Variable : bacteria  
N Mean Std Dev Std Error Minimum Maximum 
3 0.1908667 0.0809090 0.0467128 0.1171000 0.2774000 
      
135 
 
APPENDIX C (continued) 
Table C.4 (continued) GLM procedure and analysis of changes in LNTri concentrations after 
incubation   
 
LNTri 
 
The GLM Procedure 
Dependent Variable: bacteria  
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 7 10.40429360 1.48632766 37.76 <.0001 
Error 15 0.59038943 0.03935930   
Corrected Total 22 10.99468303    
 
R-Square Coeff Var Root MSE bacteria Mean 
0.946302 25.91780 0.198392 0.765465 
 
Source DF Type III SS Mean Square F Value Pr > F 
nutri 7 10.40429360 1.48632766 37.76 <.0001 
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